Page last updated: 2024-12-06

nicorandil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nicorandil is a potassium channel opener and a nitric oxide (NO) donor. It is used as a vasodilator to treat angina. It is synthesized by reacting 3-hydroxypyridine with 2-chloro-N-(2-hydroxyethyl)-N-methylacetamide. Nicorandil acts by opening ATP-sensitive potassium (KATP) channels, leading to hyperpolarization of vascular smooth muscle cells, which relaxes the blood vessels. It also stimulates NO production, which further dilates blood vessels and reduces vascular resistance. Nicorandil is studied for its potential benefits in treating various cardiovascular conditions, including angina, hypertension, heart failure, and peripheral artery disease. Research on nicorandil focuses on its mechanisms of action, its therapeutic efficacy, and its potential side effects.'

Nicorandil: A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nicorandil : A pyrimidinecarboxamide that is nicotinamide in which one of the hydrogens attached to the carboxamide nitrogen is replaced by a 2-(nitrooxy)ethyl group. It has both nitrate-like and ATP-sensitive potassium channel activator properties, and is used for the prevention and treatment of angina pectoris. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID47528
CHEMBL ID284906
CHEBI ID31905
SCHEMBL ID34547
MeSH IDM0029846

Synonyms (110)

Synonym
AC-4690
HMS3268L19
HMS3393N16
AB00639978-09
BRD-K97752965-001-01-6
gtpl2411
rp-46417
dancor
adancor
sigmart
sg-75
ikorel
nicorandilum [inn-latin]
n-(2-hydroxyethyl)nicotinamide nitrate
brn 0481451
n-(2-hydroxyethyl)nicotinamide nitrate (ester)
2-(nicotinamido)ethyl nitrat
2-nicotinamidoethyl nitrate
3-pyridinecarboxamide, n-(2-(nitrooxy)ethyl)-
sg 75
3-pyridinecarboxamide, n-(2-(nitroxy)ethyl)-
einecs 265-514-1
NCGC00025357-01
65141-46-0
nicorandil
MLS001424162
smr000466365
MLS000759488
cpd000466365
sigmart (tn)
nicorandil (jp17/usan/inn)
D01810
NCGC00025357-02
HMS2089L12
HMS2051N16
n-[2-(nitrooxy)ethyl]pyridine-3-carboxamide
2-(pyridine-3-carboxamido)ethyl nitrate
N0837
CHEMBL284906
chebi:31905 ,
MLS002222323
2-(pyridine-3-carbonylamino)ethyl nitrate
A834984
AKOS001589705
HMS2095E14
cas-65141-46-0
dtxcid6025692
dtxsid8045692 ,
tox21_110968
HMS2232A06
CCG-101045
nicorandilum
nicorandil [usan:inn:ban:jan]
unii-260456ham0
260456ham0 ,
FT-0602677
AB04467
S1971
AKOS015855406
HMS3371N18
nicorandil [mi]
nicorandil [inn]
nicorandil [who-dd]
nicorandil [usan]
nicorandil [mart.]
nicorandil [ep monograph]
nicorandil [jan]
HY-B0341
MLS006010701
NC00295
SCHEMBL34547
NCGC00025357-04
tox21_110968_1
HS-0049
AB00639978-08
2-[(pyridin-3-ylcarbonyl)amino]ethyl nitrate
perisalol
AKOS025149378
n-[2-(nitrooxy)ethyl]-3-pyridinecarboxamide
LBHIOVVIQHSOQN-UHFFFAOYSA-N
3-pyridinecarboxamide, n-[2-(nitrooxy)ethyl]-
2-(nicotinamido)ethyl nitrate
AB00639978_11
AB00639978_10
mfcd00186520
F0005-2298
DB09220
STL445540
SR-01000597534-5
sr-01000597534
SR-01000597534-1
HMS3655P05
HMS3712E14
SW197675-3
bdbm50247908
nicorandil (ikorel)
HMS3677G17
2-(pyridin-3-ylformamido)ethyl nitrate
BCP09434
HMS3413G17
Q862989
T72780
nicorandil- bio-x
BN164649
n-(2-(nitrooxy)ethyl)-3-pyridinecarboxamide
nicorandilo
2-(pyridine-3-carbylamino) ethyl nitrate
2-[(pyridin-3-yl)formamido]ethyl nitrate
EN300-1719807
Z57965636

Research Excerpts

Overview

Nicorandil is an anti-ischemic, ATP-sensitive potassium (KATP) channel opener drug. It has proved its effectiveness against hepatic Ischemia/Reperfusion (I/R) injury.

ExcerptReferenceRelevance
"Nicorandil is an anti-ischemic, ATP-sensitive potassium (KATP) channel opener drug and has proved its effectiveness against hepatic Ischemia/Reperfusion (I/R) injury."( Subnormothermic isolated organ perfusion with Nicorandil increased cold ischemic tolerance of liver in experimental model.
Erlitz, L; Hardi, P; Ibitamuno, C; Jancsó, G; Kasza, B; Sétáló, G; Takács, I; Telek, V; Vecsernyés, M, 2022
)
1.7
"Nicorandil is a type of nicotinamide ester used for the treatment of angina and ischaemic heart disease. "( [Ulcers in vulva and perineum induced by an anti-anginal drug].
Haubjerg, L; Lundby, L; Meinert, M; Nathan, T, 2022
)
2.16
"Nicorandil (NCO) is an antianginal agent first discovered in the late 1970s with a uniquely dual mechanism of action."( Cardioprotective and Antianginal Efficacy of Nicorandil: A Comprehensive Review.
Carey, M; Elshaikh, A; Goel, H; Goyal, D; Krinock, M; Nadar, SK, 2023
)
1.89
"Nicorandil is a well-known antianginal agent, which has been recommended as one of the second-line treatments for chronic stable angina as justified by the European guidelines. "( Nicorandil: A drug with ongoing benefits and different mechanisms in various diseased conditions.
Ahmed, LA,
)
3.02
"Nicorandil is an anti-anginal agent acting to improve microvascular circulation and to increase coronary blood flow."( Effects of nicorandil infusion on ECG parameters in patients with unstable angina pectoris and percutaneous coronary intervention.
Chen, K; Gong, M; Li, G; Liu, T; Liu, Y; Tse, G; Wang, W; Wu, L; Yin, L; Zhang, X, 2020
)
1.67
"Nicorandil is a hybrid between nitrates and K"( Nicorandil, a K
Abe, K; Enzan, K; Horiguchi, T; Kimura, T; Masaki, Y; Nishikawa, T, 2020
)
3.44
"Nicorandil (NIC) is an ATP-sensitive potassium (K"( Ameliorative effect of nicorandil in ovarian ischemia-reperfusion-induced injury in rats: role of potassium channel.
Abdel-Gaber, SA; Abdel-Hafez, SMN; Abdelzaher, WY; Atta, M, 2020
)
1.59
"Nicorandil 2 mg is a safe and practical alternative for patients who consume caffeine-containing products before the test or have contraindications for adenosine/ATP. "( Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: Comparison with intracoronary papaverine.
Arai, T; Masaki, R; Matsumoto, H; Mikuri, M; Ogura, K; Oishi, Y; Okada, N; Sakai, R; Shinke, T; Tanaka, H, 2020
)
2.29
"Nicorandil is an anti-anginal vasodilator drug acts by increasing nitric oxide bioavailability and opening of the K"( Hypothesis: The potential therapeutic role of nicorandil in COVID-19.
Ashour, H; Elmorsy, S; Elsayed, MH; Harb, IA, 2020
)
1.54
"Nicorandil is a representative antianginal drug that has dual properties of a nitrate and adenosine triphosphate-sensitive potassium (KATP) channel agonist; however, its effects on integrated cardiac function have not been fully understood. "( Inotropic Effects of Nicorandil on Cardiac Contractility Assessed by Left Ventricular Pressure-Volume Relationship Analyses in Anesthetized Monkeys.
Chiba, K; Ishizaka, T; Maeda, Y; Mori, K; Yoshimatsu, Y, 2018
)
2.24
"Nicorandil is an antianginal drug that has anti-inflammatory property. "( Nicorandil alleviates ovalbumin-induced airway inflammation in a mouse model of asthma.
El-Kashef, DH, 2018
)
3.37
"Nicorandil is an additional option in preventing CIN."( Preventive effect of nicorandil on contrast-induced nephropathy: a meta-analysis of randomised controlled trials.
Hu, Q; Li, S; Liu, Y; Wang, L, 2018
)
1.52
"Nicorandil is an antianginal agent with a dual mechanism of action. "( NICORANDIL EFFICACY IN THE TREATMENT OF ISCHEMIC HEART DISEASE (REVIEW).
Gabunia, L; Gongadze, N; Gvishiani, M; Makharadze, T,
)
3.02
"Nicorandil, which is a mitochondrial ATP-sensitive potassium channel opener, is believed to improve perioperative myocardial injury (PMI) in patients undergoing percutaneous coronary intervention (PCI), but recent studies have shown that nicorandil treatment did not improve functional and clinical outcomes in patients with angina pectoris who underwent elective PCI. "( Effects of mitochondrial ATP-sensitive potassium channel activation (nicorandil) in patients with angina pectoris undergoing elective percutaneous coronary interventions: A meta-analysis of randomized controlled trials.
Chen, T; Fang, X; Huang, J; Xu, X; Zheng, J; Zhu, H, 2019
)
2.19
"Nicorandil is an adenosine triphosphate-sensitive potassium channel opener with additional antioxidant properties. "( Nicorandil prevents doxorubicin-induced human umbilical vein endothelial cell apoptosis.
Chen, CC; Cheng, TH; Hao, WR; Hong, HJ; Liu, JC; Sung, LC, 2019
)
3.4
"Nicorandil is a promising antidote against doxorubicin-induced nephrotoxicity by neutralizing all toxicity mechanisms caused by doxorubicin through normalizing inflammatory cascade of TLR4/MAPK P38/NFκ-B."( Nicorandil combats doxorubicin-induced nephrotoxicity via amendment of TLR4/P38 MAPK/NFκ-B signaling pathway.
Abd El-Raouf, OM; Gad, AM; Kandeil, MA; Khalaf, MM; Khames, A, 2019
)
2.68
"Nicorandil is an antianginal drug used for 20 years in Japan and introduced in France in 1994. "( Corneal perforation: another side effect of nicorandil.
Campolmi, N; Cinotti, E; Forest, F; Gain, P; Gauthier, AS; Guy, C; Philippe-Zech, C; Thuret, G, 2014
)
2.11
"Nicorandil is an anti-anginal medication known to cause oral ulceration and skin lesions in the perianal and peristomal regions and around surgical wounds."( Ulceration of the nasal dorsum: a rare cause?
Hopkins, C; Joshi, A; Salim, F, 2014
)
1.12
"Nicorandil is a potent drug with a dual mechanism of action which results in its wide application in treating angina patients. "( Preparative isolation and high-resolution mass identification of 10 stressed study degradants of nicorandil tablets.
Malipeddi, H; Prakash, L; Subbaiah, BV, 2015
)
2.08
"Nicorandil is a commonly used antianginal agent, which has both nitrate-like and ATP-sensitive potassium (K ATP ) channel activator properties. "( Intractable hyperkalemia due to nicorandil induced potassium channel syndrome.
Chowdhry, V; Mohanty, BB,
)
1.86
"Nicorandil is a vasodilatory drug used to relieve angina symptoms. "( Use of nicorandil is Associated with Increased Risk for Gastrointestinal Ulceration and Perforation- A Nationally Representative Population-based study.
Chang, SS; Chen, YS; Gabriel Lee, MT; Hsu, WT; Lee, CC; Lee, SH, 2015
)
2.31
"Nicorandil is a drug characterized by the coupling of a nitric oxide (NO) donor to nicotinamide. "( Nicorandil inhibits neutrophil recruitment in carrageenan-induced experimental pleurisy in mice.
Araújo, DP; Augusto, PS; Batista, CR; César, IC; Coelho, MM; Coura, GM; de Fátima, Â; Godin, AM; Klein, A; Machado, RR; Matsui, TC; Melo, IS; Ribeiro, LS; Souza, DG, 2015
)
3.3
"Nicorandil is a popular anti-anginal drug in Europe and Japan. "( Nicorandil, Gastrointestinal Adverse Drug Reactions and Ulcerations: A Systematic Review.
Deosaran, J; Ford, I; Leslie, SJ; Pisano, U; Rushworth, GF; Stewart, D; Watson, AJ, 2016
)
3.32
"Nicorandil is a vasodilator with dual potassium channel opening and nitrate properties."( Intravenous nicorandil for treatment of the urgent phase acute heart failure syndromes: A randomized, controlled trial.
Fujinaga, H; Fujisawa, K; Harada, K; Harada, T; Iima, T; Kageyama, N; Kawata, A; Okada, A; Okumura, T; Saito, A; Shigekiyo, M; Terada, N; Yamamoto, H; Yamamoto, T, 2017
)
1.56
"Nicorandil is an inexpensive drug, and the reduction in cost of surgery by avoiding intra-aortic balloon pump insertion is an added advantage."( Nicorandil Infusion During Off-Pump Coronary Artery Bypass Grafting Reduces Incidence of Intra-aortic Balloon Pump Insertion.
Deval, MM; Jacob, RV; Jagdale, L; Kaul, SK; Kumar, A; Saha, KK,
)
2.3
"Nicorandil is a balanced vasodilator that acts as both NO donor and arterial K(+) ATP channel opener."( Vasodilator Therapy: Nitrates and Nicorandil.
Kaski, JC; Tarkin, JM, 2016
)
1.43
"Nicorandil is a hybrid agent with adenosine triphosphated (ATP)-sensitive K+ (KATP) channel opener and nitrate properties."( Delayed reendothelialization with rapamycin is rescued by the addition of nicorandil in balloon-injured rat carotid arteries.
Chen, JS; Chen, YD; Li, B; Ma, Q; Tian, F; Zhang, Y; Zhang, YQ; Zhou, Y, 2016
)
1.39
"Nicorandil is a hybrid angina therapeutic agent that has nitric oxide (NO) action and the ability to open ATP-sensitive K"( Nicorandil inhibits osteoclast differentiation in vitro.
Amano, H; Iwaki, F; Ohura, K, 2016
)
3.32
"(1) Nicorandil is a vasodilator with limited efficacy, marketed for symptomatic relief of angina pectoris. "( Nicorandil: serious gastrointestinal ulceration.
, 2008
)
2.35
"Nicorandil is a member of PCOs, with a special chemical structure."( Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease?
Abdollahi, M; Hosseini-Tabatabaei, A, 2008
)
1.07
"Nicorandil is a potent K(ATP) opener and clinical application of nicorandil also can reduce myocardial damage during anesthetic management of patients undergoing off-pump CABG and patients with cardiac risks undergoing non-cardiac operations."( [Myocardial preconditioning in anesthesia: from bench to bedside].
Hayashi, Y; Yamanaka, H, 2009
)
1.07
"Nicorandil is a hybrid of a nitrate and a potassium channel opener."( The effect of intracoronary nicorandil on coronary myocardial bridging.
Cho, JR; Choi, S; Jang, Y; Jung, JH; Kim, MK; Lee, N; Lee, SH; Min, PK; Park, KH; Park, WJ; Sung, CW, 2009
)
1.37
"Nicorandil is a cardioprotective drug which is used in the prophylaxis and long-term treatment of angina pectoris. "( Nicorandil induced perianal ulceration.
Angel, C; Baraza, W; Chelham, W; Garner, J; Shrestha, BM; Tiernan, JP,
)
3.02
"Nicorandil is a vasodilator that both opens potassium channels and has nitrate effects. "( Efficacy and safety of nicorandil therapy in patients with acute heart failure.
Asai, K; Hata, N; Kobayashi, N; Mizuno, K; Shinada, T; Shirakabe, A; Yokoyama, S, 2010
)
2.11
"Nicorandil is an antiangina drug with minor efficacy, which is known to cause painful ulceration of the gastrointestinal tract (from mouth to anus), and possibly the cornea. "( Painful chronic ulceration linked with nicorandil: the vagina too.
, 2010
)
2.07
"Nicorandil is an adenosine triphosphate-sensitive potassium channel opener that combines an organic nitrate and a nicotinamide group which respectively confer to nicorandil the additional properties of being a nitric oxide (NO) donor and antioxidant; it also induces vasodilation, decreases the blood pressure, and protects the heart. "( Nicorandil attenuates cyclic strain-induced endothelin-1 expression via the induction of activating transcription factor 3 in human umbilical vein endothelial cells.
Chao, HH; Chen, JJ; Cheng, TH; Hong, HJ; Liu, JC; Sung, LC, 2011
)
3.25
"Nicorandil is an antianginal medication increasingly used in the treatment of severe ischemic heart disease. "( Colonic and parastomal ulceration related to nicorandil.
Payne, CJ; Whitelaw, SC, 2011
)
2.07
"Nicorandil is an orally available drug that can act as a nitric oxide donor, an antioxidant, and an ATP-dependent K channel activator. "( Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.
Johnson, RJ; Kitagawa, W; Klawitter, J; Lanaspa, MA; Makino, H; Mathieson, PW; Miyazaki, M; Nakagawa, T; Rivard, CJ; Saleem, MA; Schreiner, GF; Tanabe, K, 2012
)
3.26
"Nicorandil is a potassium channel agonist, which is used in the treatment of ischaemic heart disease."( Perianal actinomycosis: a case study of this rare infection associated with nicorandil usage.
Ablett, DJ; Berlansky, MS; Wylie, JR, 2012
)
1.33
"Nicorandil is an original vasodilatator used to control angina by decreasing cardiac preload and afterload. "( Nicorandil: from ulcer to fistula into adjacent organs.
Barbaud, A; Guy, C; Javot, L; Marie, B; Petitpain, N; Pinzano, A; Schmutz, JL; Trechot, P, 2013
)
3.28
"Nicorandil is a mitochondrial ATP-sensitive potassium channel (mitoKATP) opener."( Cerebral protective effect of nicorandil premedication on patients undergoing liver transplantation.
Li, ST; Wang, ZP; Xia, YF; Yan, T; Zhou, YC, 2012
)
1.39
"Nicorandil is a commonly prescribed antianginal medication that has been found to be associated with painful anal ulceration. "( Nicorandil associated anal ulcers: an estimate of incidence.
Babu, H; Barakat, T; Colvin, HS; Hinson, FL; Moussa, O; Palmer, JG; Slaughter, T, 2012
)
3.26
"Nicorandil is a vasodilator used to control angina. "( Nicorandil associated anal ulceration.
Al-Ozairi, O; Fraser, A; Loudon, M; O'Kelly, T; Watson, A, 2002
)
3.2
"Nicorandil is an antianginal drug that exerts both a conventional nitrate effect and an independent ATP-dependent potassium channel-opening effect. "( Nicorandil infusion leads to good recovery from ischemia of left ventricular regional work in comparison with nitroglycerin.
Adachi, H; Hoshizaki, H; Isobe, N; Naito, S; Nogami, A; Oshima, S; Sugawara, M; Taniguchi, K; Toyama, T, 2002
)
3.2
"Nicorandil is a hybrid of nitrate and a K(ATP) channel opener that activates the sarcK(ATP) and mitoK(ATP) channels. "( Infarct size limitation by nicorandil: roles of mitochondrial K(ATP) channels, sarcolemmal K(ATP) channels, and protein kinase C.
Ichikawa, Y; Kuno, A; Matsumoto, T; Miki, T; Miura, T; Ohnuma, Y; Sakamoto, J; Shimamoto, K; Tanno, M; Tsuchida, A, 2002
)
2.05
"Nicorandil is a hybrid-type anti-anginal drug that combines a K(ATP) channel opener and a nitric oxide donor. "( Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease.
Kaikita, K; Kojima, S; Miyamoto, S; Ogawa, H; Sakamoto, T; Sugiyama, S; Yoshimura, M, 2004
)
2.16
"Nicorandil is an adenosine triphosphate sensitive K (K-ATP) channel opener and a nitric oxide donor. "( Nicorandil protects against lethal ischemic ventricular arrhythmias and up-regulates endothelial nitric oxide synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction.
Asakawa, H; Horinaka, S; Kobayashi, N; Matsuoka, H; Mori, Y; Nakano, S; Tsubokou, Y; Yabe, A; Yagi, H; Yoshida, K, 2004
)
3.21
"Nicorandil is a vasodilator used to control angina. "( Nicorandil associated anal ulceration.
Fraser, A; Loudon, M; O'Kelly, T; Suttie, S; Watson, A, 2004
)
3.21
"Nicorandil is a potassium-channel activator used in the treatment of angina pectoris. "( [Nicorandil-associated anal ulceration].
Allombert-Blaise, C; Claudy, A; Faure, M; Grandjean, JP; Ly, A; Rival, AL, 2006
)
2.69
"Nicorandil is a vasodilator used to control severe angina. "( Nicorandil-associated para-stomal ulceration: Case series.
Abdelrazeq, AS; Leveson, SH; McAdam, JG; Owen, C; Pearson, HJ; Smith, L, 2006
)
3.22
"Nicorandil is an antianginal drug used for the treatment of symptomatic coronary artery disease."( Nicorandil-associated ulcerations.
Egred, M, 2007
)
2.5
"Nicorandil is a potassium channel blocker used in the treatment of ischaemic heart disease."( Dual pathology: cervicofacial actinomycosis and nicorandil-induced oral ulceration.
Cupples, HE; McGahey, DT, 2008
)
1.32
"Nicorandil is a potassium channel activator used in the prevention and long-term treatment of angina pectoris. "( Nicorandil-induced severe perianal ulceration.
Al-Kubati, W; Atuf, M; Baker, RP; Phillips, RK, 2007
)
3.23
"Nicorandil is a rare cause of severe perianal ulceration. "( Nicorandil-induced severe perianal ulceration.
Al-Kubati, W; Atuf, M; Baker, RP; Phillips, RK, 2007
)
3.23
"Nicorandil appears to be a promising candidate for clinical use in patients with OAB."( Inhibitory effects of nicorandil, a K ATP channel opener and a nitric oxide donor, on overactive bladder in animal models.
Horie, S; Ide, H; Ishizuka, N; Kamiyama, Y; Masuda, H; Muto, S; Saito, K, 2008
)
1.38
"Nicorandil is a widely used third-line treatment for ischemic heart disease. "( Nicorandil-induced colonic ulceration: a new cause of colonic ulceration. Report of four cases.
Molloy, RG; Seow, C; Titi, MA, 2008
)
3.23
"Nicorandil is a potassium-channel activator used to prevent angina. "( [Nicorandil-induced cutaneous ulceration on a pacemaker implantation wound].
Bravard, P; Carre-Gislard, D; Jennesseaux, I, 2008
)
2.7
"Nicorandil (SG-75) is a long acting mononitrate. "( Controlled comparison of the pharmacodynamic effects of nicorandil (SG-75) and isosorbide dinitrate in man.
Belz, GG; Heinrich, J; Matthews, J; Wagner, G, 1984
)
1.96
"Nicorandil is a nicotinamide derivative with potent vasodilator properties. "( Double-blind comparison of the acute effects of two relevant doses of oral nicorandil on central hemodynamics, left ventricular function, and myocardial contractility.
Baumbach, A; Braun, U; Döring, G; Haase, KK; Karsch, KR; Voelker, W, 1995
)
1.96
"Nicorandil is a balanced arterial and venodilator that may also possess cardioprotective properties via its activation of ATP-sensitive potassium channels. "( Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil.
Fox, K; Knight, C; Purcell, H, 1995
)
1.95
"Nicorandil is an antianginal drug that causes potent coronary vasodilation of both epicardial and resistance vessels. "( Coronary microvascular response to intracoronary administration of nicorandil.
Hongo, M; Nakatsuka, T; Sekiguchi, M; Takenaka, H; Uchikawa, S; Watanabe, N, 1995
)
1.97
"Nicorandil is a new potassium channel agonist with additional nitrate properties."( Comparison of tolerance to intravenous nitroglycerin during nicorandil and intermittent nitroglycerin patch in healthy volunteers.
Billon, N; Funck-Brentano, C; Jaillon, P; Tabone, X, 1994
)
1.25
"Nicorandil is a coronary vasodilator with mixed nitrate-potassium channel agonist activity."( In vitro protective effects of nicorandil on hypothermic injury to immature cardiac myocytes: comparison with nitroglycerin.
Fukasawa, M; Fukui, K; Hirooka, S; Kohi, M; Orita, H; Washio, M, 1994
)
1.3
"Nicorandil is a mixed vasodilator combining the actions of a nitrate and a potassium channel opener."( The pharmacokinetics and haemodynamic effects of continuous nicorandil infusion in healthy volunteers.
Ferry, JJ; Froeschke, MO; Hearron, AE; Luderer, JR; Metzler, CM; Wolf, DL, 1993
)
1.25
"Nicorandil is an antianginal vasodilator having a hybrid property between nitrates and potassium channel openers, and cromakalim is a relatively specific potassium channel opener. "( Nicorandil as a nitrate, and cromakalim as a potassium channel opener, dilate isolated porcine large coronary arteries in an agonist-nonselective manner.
Mori, T; Satoh, K; Taira, N; Yamada, H, 1993
)
3.17
"Nicorandil is a unique vasodilator that combines the actions of a potassium channel activator and a nitrovasodilator. "( High-performance liquid chromatographic method for stability and pharmacokinetic studies of nicorandil.
Bachert, EL; Fung, HL, 1993
)
1.95
"Nicorandil is a compound with hybrid properties of nitrates and adenosine triphosphate (ATP)-sensitive potassium channel (KATP) opening. "( Limitation of myocardial infarct size by nicorandil after sustained ischemia in pigs.
Branzi, A; Galiè, N; Guarnieri, C; Magnani, B; Parlangeli, R; Traini, AM; Ussia, GP; Vaona, I; Zimarino, M, 1995
)
2
"Nicorandil is a clinically used nitrovasodilator that has a property as an opener of ATP-sensitive potassium (KATP) channels in vitro. "( Nicorandil augments regional ischemia-induced monophasic action potential shortening and potassium accumulation without serious proarrhythmia.
Asanagi, M; Mitamura, H; Miyazaki, T; Miyoshi, S; Moritani, K; Ogawa, S; Zhao, LS, 1995
)
3.18
"Nicorandil is a hybrid of a nitrate and a potassium channel opener, and has a potent vasodilatory effect on coronary arteries. "( Effective and safe dose of intracoronary nicorandil in man.
Fujita, M; Igawa, A; Inouc, H; Miwa, K; Yamanishi, K, 1995
)
2
"Nicorandil is an effective coronary dilator and is reported to affect both large and small coronary arteries."( [Effects of nicorandil on coronary collateral circulation depend on the donor arteries].
Aonuma, K; Hiroe, M; Igawa, M; Inada, M; Korenaga, M; Marumo, F; Ogawara, S; Okamoto, Y; Umezawa, S, 1996
)
1.39
"Nicorandil is an antianginal agent with actions at epicardial coronary arteries and arterioles, systemic arterioles, and veins. "( Nicorandil-induced peripheral vasodilatation during cardiopulmonary bypass.
Argano, V; Bajaj, BS; Falase, BA; Wall, TJ; Youhana, AY, 1999
)
3.19
"Nicorandil is a potassium channel activator used in the treatment of angina pectoris, which seems to induce specific buccal ulcerations."( [Oral ulcers induced by nicorandil: prevalence and clinicopathological aspects].
Cribier, B; Grosshans, E; Lipsker, D; Marquart-Elbaz, C,
)
1.16
"1. Nicorandil is a hybrid compound of K(+) channel opener and nitrate. "( Effects of acidosis and NO on nicorandil-activated K(ATP) channels in guinea-pig ventricular myocytes.
Hiraoka, M; Kishi, Y; Moncada, GA; Numano, F; Sawanobori, T, 2000
)
1.22
"Nicorandil is a drug with both nitrate-like and ATP-sensitive potassium-channel (K+ ATP) activating properties. "( Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.
Goa, KL; Markham, A; Plosker, GL, 2000
)
3.19
"Nicorandil is an anti-anginal agent that has been used in the United Kingdom for over 6 years and is becoming increasingly popular. "( The role of nicorandil in the treatment of myocardial ischaemia.
Easaw, J; Falase, B; Youhana, A, 2001
)
2.13
"Nicorandil is a hybrid potassium channel opener, and recent experimental studies have demonstrated its efficacy in myocardial protection against ischemia-reperfusion. "( Controlled nicorandil administration for myocardial protection during coronary artery bypass grafting under cardiopulmonary bypass.
Hayashi, Y; Ichikawa, H; Matsuda, H; Nishimura, M; Ohtake, S; Sawa, Y, 2001
)
2.14
"Nicorandil is a new antianginal agent that potentially may be used to treat the cardiovascular side effects of diabetes. "( Structural basis for the interference between nicorandil and sulfonylurea action.
Ashcroft, FM; Gribble, FM; Reimann, F, 2001
)
2.01
"Nicorandil (SG75) is a potent K+-channel activator with an additional nitro moiety. "( Mechanisms of the effects of nicorandil in the isolated rat heart during ischemia and reperfusion: a 31P-nuclear magnetic resonance study.
Ertl, G; Horn, M; Hügel, S; Neubauer, S; Schnackerz, KD; Schroeder, M, 2001
)
2.04
"Nicorandil is a K(ATP) channel opener used to treat angina. "( Safety of oral nicorandil before coronary artery bypass graft surgery.
Aouifi, A; Blanc, P; Bouvier, H; Chiari, P; Girard, C; Jegaden, O; Joseph, P; Khder, Y; Lehot, JJ; Ovize, M, 2001
)
2.11
"Nicorandil, which is an ATP-sensitive K channel opener, has been reported to protect the ischaemic myocardium. "( Effects of nicorandil on myocardial function and metabolism in the post-ischaemic reperfused heart with or without inhalation anaesthetics.
Furuya, A; Kashimoto, S; Kumazawa, T, 2002
)
2.15
"Nicorandil is an adenosine triphosphate-sensitive potassium channel opener with a nitrate-like effect. "( Blood pool contrast-enhanced MRI detects suppression of microvascular permeability in early postinfarction reperfusion after nicorandil therapy.
Chujo, M; Higgins, CB; Krombach, GA; Saeed, M, 2002
)
1.96
"Nicorandil is a potassium channel opener and nitric oxide (NO) donor, and the hypothesis was tested that these modes of action may inhibit cellular degranulation and release of tumour necrosis factor-alpha (TNF-alpha)."( Nicorandil inhibits degranulation and TNF-alpha release from RBL-2H3 cells.
Heywood, GJ; Thomas, PS, 2002
)
3.2
"1. Nicorandil is a potent vasodilator combining the effects of a nitrate with an ATP-sensitive potassium channel (K(ATP)) opener. "( Nicorandil improves myocardial high-energy phosphates in postinfarction porcine hearts.
Bache, RJ; Murakami, Y; Ochiai, K; Shimada, T; Wu, X; Zhang, J, 2002
)
2.38
"Nicorandil is a vasodilator drug that combines potassium channel opening properties with nitrate effects. "( Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans.
Giles, TD; Hearron, AE; Karalis, DG; Mohrland, JS; Pina, IL; Porter, RS; Quiroz, AC; Roffidal, L; Wolf, DL; Zaleski, R, 1992
)
1.97
"Nicorandil is a potent vasodilator with antianginal and anti-ischemic properties that acts on both the coronary and the peripheral vascular bed. "( Acute hemodynamic effects of nicorandil in coronary artery disease.
Erbel, R; Meyer, J; Treese, N, 1992
)
2.02
"Nicorandil is a potent coronary vasodilator. "( Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study.
Bucx, JJ; Henneman, JA; Hugenholtz, PG; Kelder, JC; Kerker, JP; Meeter, K; Tijssen, JG, 1992
)
2.11
"Nicorandil is a new vasodilator agent. "( Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy.
Krumenacker, M; Roland, E, 1992
)
2.05
"Nicorandil is a nicotinamide derivative with a potential role in human therapeutics because of its potent vasodilating properties. "( Clinical pharmacology of nicorandil in patients with congestive heart failure.
Bindley, PF; Binkley, PF; Jungbluth, GL; Leier, CV; MacKichan, JJ; Mohrland, JS; Tice, FD; Wolf, DL, 1992
)
2.03
"Nicorandil is a new coronary vasodilator possessing beneficial properties. "( Left ventricular effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs.
Hashimoto, K; Kinoshita, M; Ohbayashi, Y, 1990
)
2.02
"Nicorandil (SG-75) is a new organic nitrate with pronounced vasodilator properties. "( Cyclic GMP in nicorandil-induced vasodilatation and tolerance development.
Holzmann, S; Kukovetz, WR, 1987
)
2.08
"Nicorandil is thought to be a K+ channel opening agent."( Studies on the mechanism of the vasodilator action of nicorandil.
Lefer, AM; Lefer, DJ, 1988
)
1.24
"Nicorandil is a new compound that has shown potent vasodilator activities on venous and arterial beds in experimental pharmacology. "( Hemodynamic action of nicorandil in chronic congestive heart failure.
Bouthier, J; Dahan, M; Gourgon, R; Jaeger, P; Juliard, JM; Solal, AC, 1989
)
2.03
"Nicorandil is a vasodilator that acts on the venous and arterial beds of the systemic circulation. "( A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris.
Camm, AJ; Maltz, MB, 1989
)
1.94

Effects

Nicorandil has been reported to cause a concentration-dependent relaxation of isolated guinea pig trachealis. It has a trend to reduce the rate of target lesion revascularization and has a significant effect on renal hemodynamics.

Nicorandil has been applied clinically in various cardiovascular diseases such as variant or unstable angina and reperfusion-induced damage following coronary angioplasty or thrombolysis. It has dual properties and acts as a nitric oxide donor and an ATP-sensitive potassium.

ExcerptReferenceRelevance
"Nicorandil has a beneficial effect on improving coronary microvascular dysfunction (CMD)."( The effect of nicorandil in patients with cardiac syndrome X: A meta-analysis of randomized controlled trials.
Hu, Y; Jia, Q; Shi, J; Shi, S; Wei, Y; Yuan, G, 2020
)
1.64
"Nicorandil has a trend to reduce the rate of target lesion revascularization."( Nicorandil attenuates carotid intimal hyperplasia after balloon catheter injury in diabetic rats.
Chen, YD; Li, B; Ma, Q; Tian, F; Zhang, Y; Zhang, YQ; Zhou, Y, 2016
)
2.6
"Nicorandil has a significant effect on renal hemodynamics."( Effects of intravenous bolus injection of nicorandil on renal artery flow velocity assessed by color Doppler ultrasound.
Akasaka, T; Emori, H; Hozumi, T; Ino, Y; Kameyama, T; Katayama, Y; Kubo, T; Kuroi, A; Matsuo, Y; Nishiguchi, T; Orii, M; Shimamoto, Y; Takemoto, K; Tanabe, K; Tanaka, A; Taruya, A; Terada, M; Yamaguchi, T; Yamano, T, 2017
)
1.44
"Nicorandil has a hybrid property between nitrates and potassium channel openers and has been reported to cause a concentration-dependent relaxation of isolated guinea pig trachealis. "( Intravenous nicorandil prevents thiamylal-fentanyl-induced bronchoconstriction in humans.
Imanaga, K; Inoue, T; Ogawa, R; Ogura, A; Shiga, T; Wajima, Z; Yoshikawa, T, 2003
)
2.14
"Nicorandil has a salutary effect on the changes in left ventricular end-diastolic pressure during exercise in patients with hypertrophic cardiomyopathy."( Effect of nicorandil on left ventricular end-diastolic pressure during exercise in patients with hypertrophic cardiomyopathy.
Iwase, M; Izawa, H; Murohara, T; Nagata, K; Nishizawa, T; Noda, A; Somura, F; Takeichi, Y; Yokota, M, 2003
)
2.16
"Nicorandil has a myocardial protective effect during PCI in patients with UAP."( Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina.
Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DK; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, SY; Park, HW; Park, JC; Yun, KH, 2005
)
2.05
"Nicorandil has an anti-apoptotic effect on ischemic myocardium through the activation of ATP-sensitive potassium (K(ATP)) channel. "( Oral administration of nicorandil enhances the survival of ischemic skin flaps in rats.
Hiura, A; Inoue, K; Koga, M; Nakagawa, N; Qi, Z; Sumi, S; Yanai, G, 2006
)
2.09
"Nicorandil has a beneficial effect on the post-ischemic dysfunction in both SHR and WKY rats."( Effect of nicorandil on cardiac dysfunction during reperfusion in normotensive and spontaneously hypertensive rats.
Asayama, J; Inoue, D; Kobara, M; Matoba, S; Nakagawa, C; Nakagawa, M; Ohta, B; Tatsumi, T; Yamahara, Y, 1995
)
1.41
"Nicorandil has a marked relaxant effect on contractions evoked by three different vasoconstrictor agonists, and relaxes vasospasm that is resistant to conventional Ca(2+) antagonists. "( Vasorelaxant properties of nicorandil on human radial artery.
Beech, DJ; Mathew, K; Munsch, CM; Sadaba, JR, 2000
)
2.05
"Nicorandil has a protective effect in patients with acute myocardial infarction and preexisting angina treated with primary balloon angioplasty."( Nicorandil affords cardioprotection in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty: assessment with thallium-201/iodine-123 BMIPP dual SPECT.
Fukuzawa, S; Inagaki, M; Ozawa, S; Shimada, K; Sugioka, J; Tateno, K; Ueda, M,
)
3.02
"Nicorandil has a protective effect on the ischemic rabbit spinal cord, and the beneficial effect seems mediated through the activation of adenosine triphosphate-sensitive potassium channels."( The adenosine triphosphate-sensitive potassium channel opener nicorandil protects the ischemic rabbit spinal cord.
Kunihara, T; Shiiya, N; Wakamatsu, Y; Watanabe, S; Yasuda, K, 2001
)
1.99
"Nicorandil has a hybrid property between nitrates and potassium (K)-channel openers. "( Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism.
Satoh, K; Taira, N; Yoneyama, F, 1990
)
3.16
"Nicorandil has also been applied clinically in various cardiovascular diseases such as variant or unstable angina and reperfusion-induced damage following coronary angioplasty or thrombolysis."( Nicorandil: A drug with ongoing benefits and different mechanisms in various diseased conditions.
Ahmed, LA,
)
2.3
"Nicorandil has a beneficial effect on improving coronary microvascular dysfunction (CMD)."( The effect of nicorandil in patients with cardiac syndrome X: A meta-analysis of randomized controlled trials.
Hu, Y; Jia, Q; Shi, J; Shi, S; Wei, Y; Yuan, G, 2020
)
1.64
"Nicorandil has been suggested as a preventative strategy against the incidence of contrast-induced nephropathy (CIN). "( Nicorandil for the prevention of contrast-induced nephropathy: A meta-analysis of randomized controlled trials.
Jiao, Z; Li, X; Ma, X; Zhang, Y, 2018
)
3.37
"Nicorandil (NIC) has multiple beneficial cardiovascular effects on myocardial injury."( The protective effect of nicorandil on cardiomyocyte apoptosis after coronary microembolization by activating Nrf2/HO-1 signaling pathway in rats.
He, W; Li, L; Liang, J; Su, Q; Sun, Y; Wang, X, 2018
)
1.51
"Nicorandil has dual properties and acts as a nitric oxide donor and an ATP-sensitive potassium (K"( Nicorandil increased the cerebral blood flow via nitric oxide pathway and ATP-sensitive potassium channel opening in mice.
Hishiyama, S; Ishiyama, T; Kotoda, M; Matsukawa, T; Mitsui, K, 2018
)
3.37
"Nicorandil has vasodilatory effects on both the epicardial coronary arteries and the coronary microvasculature, thereby increasing coronary blood flow. "( Intravenous nicorandil versus adenosine for fractional flow reserve measurement: a crossover, randomized study.
Fujimoto, Y; Hanaoka, H; Kitahara, H; Kobayashi, Y; Nagashima, K; Nakayama, T; Nishi, T, 2018
)
2.3
"Nicorandil has a trend to reduce the rate of target lesion revascularization."( Nicorandil attenuates carotid intimal hyperplasia after balloon catheter injury in diabetic rats.
Chen, YD; Li, B; Ma, Q; Tian, F; Zhang, Y; Zhang, YQ; Zhou, Y, 2016
)
2.6
"Nicorandil has a significant effect on renal hemodynamics."( Effects of intravenous bolus injection of nicorandil on renal artery flow velocity assessed by color Doppler ultrasound.
Akasaka, T; Emori, H; Hozumi, T; Ino, Y; Kameyama, T; Katayama, Y; Kubo, T; Kuroi, A; Matsuo, Y; Nishiguchi, T; Orii, M; Shimamoto, Y; Takemoto, K; Tanabe, K; Tanaka, A; Taruya, A; Terada, M; Yamaguchi, T; Yamano, T, 2017
)
1.44
"Nicorandil has vasodilatory effects on both the epicardial coronary arteries and the coronary microvasculature, thereby increasing coronary blood flow. "( Efficacy of intravenous nicorandil for fractional flow reserve assessment: study protocol for a crossover randomised trial.
Fujimoto, Y; Hanaoka, H; Kitahara, H; Kobayashi, Y; Nagashima, K; Nakayama, T; Nishi, T; Sugimoto, K, 2016
)
2.18
"Nicorandil has protective effects on the ischemic atrial myocardium. "( Nicorandil ameliorates impulse conduction disturbances during ischemia in isolated arterially perfused canine atria.
Hirose, M; Horiuchi-Hirose, M; Nakada, T; Tsujino, N; Yamada, M; Yano, S, 2011
)
3.25
"Nicorandil has cardioprotective effects in the ischemic myocardium, mimicking ischemic preconditioning, and is thus expected to improve the prognosis of ischemic heart disease (IHD). "( Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study.
Horinaka, S; Ishimitsu, T; Kohro, T; Nagai, R; Suzuki, S; Yabe, A; Yagi, H; Yamazaki, T, 2010
)
2.19
"Nicorandil has been available in the U.K. "( Nicorandil: do the dermatological and gastrointestinal risks outweigh the benefits?
Lyon, CC; Smith, VM, 2012
)
3.26
"Nicorandil has been reported to have a cardioprotective action through activation of mitochondrial ATP-sensitive potassium (mitoK(ATP)) channels. "( Antiapoptotic effect of nicorandil mediated by mitochondrial atp-sensitive potassium channels in cultured cardiac myocytes.
Akao, M; Marbán, E; Teshima, Y, 2002
)
2.06
"Nicorandil has been reported to have a preconditioning effect which suppresses the ST-segment shift or lactate production during coronary angioplasty in patients with stable angina pectoris. "( Nicorandil-induced preconditioning as evidenced by troponin T measurements after coronary angioplasty in patients with stable angina pectoris.
Chayama, K; Matsuura, H; Sakai, K; Teragawa, H; Yamagata, T, 2002
)
3.2
"Nicorandil has a hybrid property between nitrates and potassium channel openers and has been reported to cause a concentration-dependent relaxation of isolated guinea pig trachealis. "( Intravenous nicorandil prevents thiamylal-fentanyl-induced bronchoconstriction in humans.
Imanaga, K; Inoue, T; Ogawa, R; Ogura, A; Shiga, T; Wajima, Z; Yoshikawa, T, 2003
)
2.14
"Nicorandil has a salutary effect on the changes in left ventricular end-diastolic pressure during exercise in patients with hypertrophic cardiomyopathy."( Effect of nicorandil on left ventricular end-diastolic pressure during exercise in patients with hypertrophic cardiomyopathy.
Iwase, M; Izawa, H; Murohara, T; Nagata, K; Nishizawa, T; Noda, A; Somura, F; Takeichi, Y; Yokota, M, 2003
)
2.16
"Nicorandil has been shown to induce an infarct-limiting effect similar to that induced by the early phase of ischemic preconditioning (PC). "( Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits.
Bolli, R; Shirk, G; Tang, XL; Xuan, YT; Zhu, Y, 2004
)
3.21
"Nicorandil has been shown to precipitate persistent ulcerative stomatitis in a small percentage of patients. "( Nicorandil-induced severe oral ulceration.
O'Sullivan, EM, 2004
)
3.21
"Nicorandil has a myocardial protective effect during PCI in patients with UAP."( Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina.
Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DK; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, SY; Park, HW; Park, JC; Yun, KH, 2005
)
2.05
"Nicorandil has been shown to inhibit myocyte apoptosis by opening of mitochondrial ATP-sensitive potassium (mitoK(ATP)) channels and nitrate-like effect against oxidative stress. "( Nicorandil regulates Bcl-2 family proteins and protects cardiac myocytes against hypoxia-induced apoptosis.
Keira, N; Kobara, M; Mano, A; Matsubara, H; Matsunaga, S; Nishikawa, S; Okigaki, M; Shiraishi, J; Takahashi, T; Takeda, M; Tatsumi, T, 2006
)
3.22
"Nicorandil (NCR) has been reported to have cardioprotective effects in patients with AMI. "( Nicorandil administration shows cardioprotective effects in patients with poor TIMI and collateral flow as well as good flow after AMI.
Adachi, H; Hoshizaki, H; Isobe, N; Kasama, S; Kawaguchi, R; Oshima, S; Seki, R; Taniguchi, K; Toyama, T, 2006
)
3.22
"Nicorandil has an anti-apoptotic effect on ischemic myocardium through the activation of ATP-sensitive potassium (K(ATP)) channel. "( Oral administration of nicorandil enhances the survival of ischemic skin flaps in rats.
Hiura, A; Inoue, K; Koga, M; Nakagawa, N; Qi, Z; Sumi, S; Yanai, G, 2006
)
2.09
"Nicorandil has been reported to induce cardioprotection by opening the mitochondrial K(ATP) channels. "( Nicorandil improves post-ischemic myocardial dysfunction in association with opening the mitochondrial K(ATP) channels and decreasing hydroxyl radicals in isolated rat hearts.
Arai, M; Bao, N; Chen, XH; Fujiwara, H; Kawamura, I; Kobayashi, H; Lu, C; Minatoguchi, S; Takemura, G; Wang, N; Wu, DJ; Yasuda, S, 2006
)
3.22
"Nicorandil has a beneficial effect on the post-ischemic dysfunction in both SHR and WKY rats."( Effect of nicorandil on cardiac dysfunction during reperfusion in normotensive and spontaneously hypertensive rats.
Asayama, J; Inoue, D; Kobara, M; Matoba, S; Nakagawa, C; Nakagawa, M; Ohta, B; Tatsumi, T; Yamahara, Y, 1995
)
1.41
"Nicorandil has a marked relaxant effect on contractions evoked by three different vasoconstrictor agonists, and relaxes vasospasm that is resistant to conventional Ca(2+) antagonists. "( Vasorelaxant properties of nicorandil on human radial artery.
Beech, DJ; Mathew, K; Munsch, CM; Sadaba, JR, 2000
)
2.05
"Nicorandil has a protective effect in patients with acute myocardial infarction and preexisting angina treated with primary balloon angioplasty."( Nicorandil affords cardioprotection in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty: assessment with thallium-201/iodine-123 BMIPP dual SPECT.
Fukuzawa, S; Inagaki, M; Ozawa, S; Shimada, K; Sugioka, J; Tateno, K; Ueda, M,
)
3.02
"Nicorandil has a protective effect on the ischemic rabbit spinal cord, and the beneficial effect seems mediated through the activation of adenosine triphosphate-sensitive potassium channels."( The adenosine triphosphate-sensitive potassium channel opener nicorandil protects the ischemic rabbit spinal cord.
Kunihara, T; Shiiya, N; Wakamatsu, Y; Watanabe, S; Yasuda, K, 2001
)
1.99
"Nicorandil clearly has demonstrated K(+)-channel-opening activity."( Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy.
Krumenacker, M; Roland, E, 1992
)
1.33
"Nicorandil (NCD) has remarkable coronary vasodilating effect but possesses little negative chronotropic activity."( [Efficacy of nicorandil on myocardial protection during coronary artery bypass grafting--a comparison with diltiazem].
Asada, T; Higami, T; Kawamura, T; Mukohara, N; Nishiwaki, M; Ogawa, K; Okada, K; Sakata, M; Sugimoto, T, 1992
)
1.37
"Nicorandil has a hybrid property between nitrates and potassium (K)-channel openers. "( Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism.
Satoh, K; Taira, N; Yoneyama, F, 1990
)
3.16
"Nicorandil has the following characteristics of a nitrate."( Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview.
Taira, N, 1987
)
1.23
"Nicorandil has the capacity to increase myocardial oxygen supply without increasing oxygen demand by reduction in preload and afterload."( Nicorandil: animal pharmacology.
Sakai, K, 1989
)
2.44

Actions

Nicorandil may activate KATP channel current more effectively in conditions associated with a change in intracellular proton and ADP concentrations such as cardiac ischaemia. It can inhibit the development of PAH by reducing pulmonary artery pressure and RV hypertrophy.

ExcerptReferenceRelevance
"Nicorandil will activate ATP-sensitive potassium channel (KATP). "( Use of nicorandil is associated with increased risk of incident atrial fibrillation.
Chan, CY; Chang, SN; Chen, JJ; Hsu, WT; Huang, PS; Huang, TY; Hwang, JJ; Lee, CC; Liu, SS; Tehrani, B; Tsai, CT, 2022
)
2.62
"Nicorandil can inhibit renal tubular damage and tubulointerstitial fibrosis by reducing the effects of oxidative stress after PUUO."( Effects of nicorandil on renal function and histopathology in rats with partial unilateral ureteral obstruction.
Firat, T; Ozturk, H; Tekce, BK; Yilmaz, F, 2017
)
1.57
"The nicorandil group showed lower concentrations of TnT, suggesting that intraoperative administration of nicorandil may provide a degree of myocardial protection in CABG surgery."( Cardioprotective effects of nicorandil in patients undergoing on-pump coronary artery bypass surgery.
Kotake, Y; Takeda, J; Yamada, T; Yamamoto, S, 2008
)
1.2
"Oral nicorandil may inhibit cardiac death of hemodialysis patients without obstructive coronary artery disease."( Oral nicorandil for prevention of cardiac death in hemodialysis patients without obstructive coronary artery disease: a propensity-matched patient analysis.
Hashimoto, T; Iwamoto, N; Kobayashi, H; Murakawa, M; Nishida, M; Nishimura, M; Okamoto, Y; Ono, T; Sakoda, C; Sato, N; Takahashi, H; Tokoro, T; Yamazaki, S, 2011
)
1.4
"Nicorandil may also activate Maxi K(+) channels, possibly through the NO-cGMP pathway, and the interaction of K ATP channels and Maxi K(+) channels may affect the relaxant effect of nicorandilin bovine tracheal smooth muscle."( The relaxant action of nicorandil in bovine tracheal smooth muscle.
Ishii, K; Moriuchi, H; Nakahara, T; Sakamoto, K; Yunoki, M, 2012
)
1.41
"Nicorandil can inhibit the development of PAH by reducing pulmonary artery pressure and RV hypertrophy."( Nicorandil prevents right ventricular remodeling by inhibiting apoptosis and lowering pressure overload in rats with pulmonary arterial hypertension.
Bi, LQ; Cao, Q; Wang, H; Wang, Q; Xie, WP; Yu, YZ; Zuo, XR, 2012
)
2.54
"Nicorandil is able to inhibit TNFalpha release from lymphocytes, which requires the dual modes of both potassium channel opening and the nitrate moiety."( Nicorandil inhibits the release of TNFalpha from a lymphocyte cell line and peripheral blood lymphocytes.
Di Girolamo, N; Heywood, GJ; Thomas, PS; Wei, XM, 2003
)
2.48
"Nicorandil did not increase the anti-aggregation activity of endothelial NO when endothelial cells were pre-treated with superoxide dismutase or 4-(2-aminophenyl)-benzenesulfonyl fluoride, an inhibitor of NADPH oxidase."( Nicorandil enhances the effect of endothelial nitric oxide under hypoxia-reoxygenation: role of the KATP channel.
Ishizuka, N; Saitoh, K; Sakagami, H; Tajima, M, 2008
)
2.51
"Nicorandil is a rare cause of severe perianal ulceration. "( Nicorandil-induced severe perianal ulceration.
Al-Kubati, W; Atuf, M; Baker, RP; Phillips, RK, 2007
)
3.23
"Nicorandil was found to increase the rate of VO2, increase during the onset of constant work rate exercise, probably as a result of an improved response in cardiac output."( Effects of nicorandil on kinetics of oxygen uptake at the onset of exercise in patients with coronary artery disease.
Adachi, H; Hiroe, M; Kano, H; Koike, A; Korenaga, M; Marumo, F; Miyahara, Y; Shimizu, N; Sugimoto, K; Yajima, T, 1995
)
1.4
"Nicorandil may activate KATP channel current more effectively in conditions associated with a change in intracellular proton and ADP concentrations such as cardiac ischaemia."( Intracellular acidification and ADP enhance nicorandil induction of ATP sensitive potassium channel current in cardiomyocytes.
Jahangir, A; Kurachi, Y; Terzic, A, 1994
)
1.99
"Nicorandil may suppress premature ventricular contractions when they occur mainly at a low heart rate."( Clinical suppression of bradycardia dependent premature ventricular contractions by the potassium channel opener nicorandil.
Arita, M; Fujino, T; Fukumoto, T; Ito, M; Kagiyama, H; Saikawa, T; Sakata, T; Takahashi, N, 1998
)
1.95
"Nicorandil appears to enhance cardiac eNOS expression via activation of a K(ATP) channel."( Nicorandil enhances cardiac endothelial nitric oxide synthase expression via activation of adenosine triphosphate-sensitive K channel in rat.
Hara, K; Hara, S; Higashi, T; Horinaka, S; Kobayashi, N; Matsuoka, H, 2001
)
2.47
"Nicorandil is able to inhibit degranulation and TNF-alpha release of RBL cells stimulated through the IgE receptor, and requires both the K+ opening and nitric oxide donor activity, which may represent a novel method for inhibiting cytokine release."( Nicorandil inhibits degranulation and TNF-alpha release from RBL-2H3 cells.
Heywood, GJ; Thomas, PS, 2002
)
3.2
"The nicorandil-induced increase in heart rate and maxLVdP/dt, being substantially attenuated in conscious pigs after treatment with propranolol, can be ascribed to a reflex activation of the sympathetic nervous system following the fall in arterial pressure."( Nicorandil-induced changes in the distribution of cardiac output and coronary blood flow in pigs.
Duncker, DJ; Rensen, RJ; Sassen, LM; Saxena, PR; Schmeets, IO; Verdouw, PD, 1987
)
2.2

Treatment

Nicorandil treatment reversed these changes of oxidative stress marker levels. The drug also inhibited the increase in BAX, the decrease in BCL2, activation of caspase-3 and apoptosis by mutant HSPB5.

ExcerptReferenceRelevance
"Nicorandil treatment reversed these changes of oxidative stress marker levels."( Effects of nicorandil on systemic inflammation and oxidative stress induced by percutaneous coronary intervention in patients with coronary heart disease.
Li, J; Xu, X; Zong, Y, 2021
)
1.73
"Nicorandil pretreatment attenuated cardiac dysfunction and myocardial injury following CME. "( Nicorandil protects against coronary microembolization-induced myocardial injury by suppressing cardiomyocyte pyroptosis via the AMPK/TXNIP/NLRP3 signaling pathway.
Li, H; Li, L; Li, T; Liu, T; Liu, Y; Shu, J; Xie, J, 2022
)
3.61
"Nicorandil pretreatment inhibits cardiomyocyte pyroptosis and alleviates CME-induced myocardial injury via the AMPK/TXNIP/NLRP3 signaling pathway."( Nicorandil protects against coronary microembolization-induced myocardial injury by suppressing cardiomyocyte pyroptosis via the AMPK/TXNIP/NLRP3 signaling pathway.
Li, H; Li, L; Li, T; Liu, T; Liu, Y; Shu, J; Xie, J, 2022
)
3.61
"In nicorandil treatment groups, intervals of QTd and Tp-e in patients post-PCI were significantly shorter than that in control and pre-PCI (p < .05)."( Effects of nicorandil infusion on ECG parameters in patients with unstable angina pectoris and percutaneous coronary intervention.
Chen, K; Gong, M; Li, G; Liu, T; Liu, Y; Tse, G; Wang, W; Wu, L; Yin, L; Zhang, X, 2020
)
1.46
"Nicorandil pretreatment at 4 hours and 3 days before ischemia demonstrated significant motor function preservation; administration 10 minutes before ischemia showed no neuroprotection."( Optimizing Nicorandil for Spinal Cord Protection in a Murine Model of Complex Aortic Intervention.
Aftab, M; Cheng, L; Cleveland, JC; Fullerton, DA; Ghincea, CV; Ikeno, Y; Meng, X; Reece, TB; Roda, GF; Weyant, MJ, 2022
)
1.83
"Nicorandil treatment suppressed protein kinase C/nicotinamide adenine dinucleotide phosphate oxidases system activities by reducing cytoplasmic free calcium level in skeletal muscle cells exposed to high glucose."( Nicorandil attenuates high glucose-induced insulin resistance by suppressing oxidative stress-mediated ER stress PERK signaling pathway.
Guan, G; He, C; He, T; Liu, P; Liu, Z; Pan, S; Wang, J; Zhang, Y; Zhao, N; Zhu, H; Zhu, L, 2021
)
2.79
"Nicorandil treatment caused an increase in these enzyme activities."( Effects of nicorandil on renal function and histopathology in rats with partial unilateral ureteral obstruction.
Firat, T; Ozturk, H; Tekce, BK; Yilmaz, F, 2017
)
1.57
"Nicorandil treatment seven days before CME induction effectively inhibited myocardial inflammation, ameliorated myocardial injury, and improved cardiac function, mainly by inhibiting Toll-like receptor 4 (TLR4)-mediated myeloid differentiation primary response protein 88 (MyD88)-dependent nuclear factor-kappa B (NF-κB) signaling."( Role of TLR4/MyD88/NF-κB signaling pathway in coronary microembolization-induced myocardial injury prevented and treated with nicorandil.
Kong, B; Lv, X; Qin, Z; Su, Q; Sun, Y; Ye, Z, 2018
)
1.41
"Nicorandil treatment significantly reduced total mortality in PPCI (Peto OR = 0.44, 95%CI 0.25-0.79, P = 0.006) and EPCI (Peto OR = 0.41, 95%CI 0.25-0.67, P = 0.0004), cardiovascular death in both PPCI (Peto OR = 0.41, 95%CI 0.20-0.84, P = 0.01) and EPCI (Peto OR = 0.40, 95%CI 0.20-0.80, P = 0.009), and heart failure in PPCI (RR = 0.36, 95%CI 0.22-0.59, P < 0.0001)."( Effects of Nicorandil on All-Cause Mortality and Cardiac Events in CAD Patients Receiving PCI.
Du, L; Li, J; Liu, G; Yao, X; Yu, Q; Zhang, X, 2019
)
1.63
"Nicorandil pretreatment resulted in a significant decrease in nephrotoxicity biomarkers, oxidative stress markers, inflammatory mediators and prevented apoptosis through decreasing BAX and increasing Bcl-2 in renal tissues."( Nicorandil combats doxorubicin-induced nephrotoxicity via amendment of TLR4/P38 MAPK/NFκ-B signaling pathway.
Abd El-Raouf, OM; Gad, AM; Kandeil, MA; Khalaf, MM; Khames, A, 2019
)
2.68
"Nicorandil pretreatment was able to abolish these stress-induced changes through a mechanism that involved the nitric oxide-cyclic guanosine monophosphate pathway and mitochondrial adenosine triphosphate-sensitive potassium channels."( Nicorandil, a Nitric Oxide Donor and ATP-Sensitive Potassium Channel Opener, Protects Against Dystrophin-Deficient Cardiomyopathy.
Afzal, MZ; Childers, MK; Ebert, AD; Gastonguay, C; Ge, ZD; Guan, X; Mack, DL; McGivern, JV; Reiter, M; Strande, JL, 2016
)
2.6
"Nicorandil pretreatment in rat fed on normal diet enhanced the hemodynamics significantly (P<0.05) along with a substantial reduction in the mitochondrial dysfunction (measured by high ADP to oxygen consumption ratio, respiratory control ratio, enzyme activities and less swelling behavior) when subjected to IR."( Vascular calcification abrogates the nicorandil mediated cardio-protection in ischemia reperfusion injury of rat heart.
Amirthalingam, SK; Gopalakrishnan, S; Kurian, GA; Murali, J; Ravindran, S, 2017
)
1.45
"Nicorandil pretreatment depicted a higher preventive index in indomethacin- (89.8%) and alcohol-induced (77.7%) acute ulceration."( Gastroprotective effect of nicorandil in indomethacin and alcohol-induced acute ulcers.
Abdel-Hamid, NM; Abdel-Raheim, SR; El-Moselhy, MA, 2009
)
1.37
"Nicorandil treatment reduced the incidence of TIMI flow grade < or =2 in 1,337 patients of 10 studies (risk ratio 0.63; 95% confidence interval (CI) 0.44 to 0.91)."( Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis.
Date, M; Fujii, K; Higuchi, Y; Imai, M; Inoue, K; Ito, H; Ito, N; Iwakura, K; Kimura, R; Koyama, Y; Kubota, A; Nagai, H; Okamura, A; Okazaki, Y; Ozawa, M; Shibuya, M; Suenaga, H; Toyoshima, Y, 2009
)
2.52
"Nicorandil treatment resulted in an additional 0.5-1 elastic lamella in the aorta and decreased total protein, collagen and elastin content in the aortic wall at all ages."( Effects of chronic treatment with a low dose of nicorandil on the function of the rat aorta during ageing.
Faury, G; Lavanchy, N; Mecham, RP; Mezin, P; Raveaud, S; Starcher, B; Verdetti, J, 2009
)
1.33
"Nicorandil treatment also inhibited the increase in BAX, the decrease in BCL2, activation of caspase-3 and apoptotic cell death by mutant HSPB5."( Cardioprotective effect of nicorandil, a mitochondrial ATP-sensitive potassium channel opener, prolongs survival in HSPB5 R120G transgenic mice.
Marunouchi, T; Nishigori, H; Sanbe, A; Tanonaka, K; Tanoue, A; Yamauchi, J, 2011
)
1.39
"Nicorandil treatment may reduce the level of BNP by reducing the central blood pressure in CKD patients."( Effects of nicorandil on the reduction of BNP levels in patients with chronic kidney disease.
Hamono, T; Inoue, K; Isaka, Y; Kawada, N; Kimura, T; Kitamura, H; Matsui, I; Nagasawa, Y; Obi, Y; Rakugi, H; Sakata, Y; Shinzawa, M, 2011
)
2.2
"Nicorandil treatment was associated with better myocardial perfusion and a better functional and clinical outcome than PCI alone, and this beneficial effect was maintained for a long time, particularly in patients with anterior AMI."( Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction.
Fujii, K; Ikushima, M; Ito, H; Iwakura, K; Kato, A; Kawano, S; Kimura, R; Masuyama, T; Ogihara, T; Sugimoto, K; Tanaka, K, 2003
)
1.42
"Nicorandil pretreatment resulted in the induction of myocardial preconditioning independent of the severity of ischaemia."( Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil.
Fujiwara, H; Hirose, T; Iwama, M; Matsuno, Y; Matsuo, H; Minatoguchi, S; Segawa, T; Tanaka, S; Tomita, M; Watanabe, S; Yamaki, T; Yasuda, S, 2003
)
1.97
"Nicorandil treatment following PCI for AMI is convenient and may reduce the rate of cardiac events by inhibiting ventricular arrhythmias, thereby potentially improving the prognosis."( [Suppressive effect of nicorandil in ventricular arrhythmias after reperfusion therapy in patients with acute myocardial infarction].
Hara, H; Horinaka, S; Iemura, T; Matsuoka, H; Tsuboko, Y; Yabe, A; Yagi, H; Yoshida, K, 2007
)
1.37
"Nicorandil treatment did not change the altered heart rate variability in either time domain or spectral analysis."( Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina.
Chang, MS; Chen, JW; Hsu, NW; Lee, WL; Lin, SJ; Ting, CT; Wang, SP, 1997
)
1.3
"Nicorandil pretreatment significantly decreased the incidence and duration of reperfusion-induced life-threatening arrhythmias and increased the number of animals that survived without developing any arrhythmia."( Effects of nicorandil administration on survival rate and arrhythmias during reperfusion in anesthetized rabbits.
Das, B; Karanth, KS; Sarkar, C, 2001
)
1.42
"Treatment with nicorandil mitigated left ventricular enlargement, improved the capacity of myocardial diastolic-contractility, decreased cardiomyocyte apoptosis, and inhibited myocardial fibrosis development post-MI. "( Nicorandil alleviates cardiac remodeling and dysfunction post -infarction by up-regulating the nucleolin/autophagy axis.
Deng, HF; Liu, K; Liu, MD; Ma, H; Wang, KK; Wang, N; Xiao, XZ; Zhu, LL; Zou, J, 2022
)
2.52
"Treatment with nicorandil alleviated myocardial remodeling post-MI through up-regulating the expression of nucleolin, and subsequently promoting autophagy, followed by regulating TGF-β/Smad signaling pathway."( Nicorandil alleviates cardiac remodeling and dysfunction post -infarction by up-regulating the nucleolin/autophagy axis.
Deng, HF; Liu, K; Liu, MD; Ma, H; Wang, KK; Wang, N; Xiao, XZ; Zhu, LL; Zou, J, 2022
)
2.52
"Pretreatment with nicorandil reduced serum levels of aminotransferases, bilirubin, GGT and LDH, and increased serum level of albumin."( Hepatoprotective effect of nicorandil against acetaminophen-induced oxidative stress and hepatotoxicity in mice via modulating NO synthesis.
El-Kashef, DH; Sharawy, MH, 2023
)
1.53
"Treatment with nicorandil for 6 months after primary PCI was not associated with any improvement in infarct size, CMR-determined cardiac function, and outcomes in STEMI patients."( The effect of nicorandil on cardiac function and clinical outcomes in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a randomised trial.
Ahn, J; Cha, KS; Choe, JC; Choi, JH; Kim, E; Kim, MS; Lee, HC; Lee, HW; Lee, JW; Oh, JH; Park, JH; Park, JS; Park, TS, 2023
)
1.62
"Treatment of nicorandil significantly reduced the incidence of CIN as compared with controls (risk ration [RR]: 0.38, 95% confidence interval [CI]: 0.19 ~ 0.74, P = .005) with moderate heterogeneity (I"( Nicorandil for the prevention of contrast-induced nephropathy: A meta-analysis of randomized controlled trials.
Jiao, Z; Li, X; Ma, X; Zhang, Y, 2018
)
2.28
"Pretreatment with nicorandil (100 µM) effectively abolished the influence of hypoxia on HPAECs."( Nicorandil inhibits hypoxia-induced apoptosis in human pulmonary artery endothelial cells through activation of mitoKATP and regulation of eNOS and the NF-κB pathway.
Wang, H; Wang, Q; Wu, H; Xie, L; Xie, W; Yu, Y; Zuo, X, 2013
)
2.16
"Pretreatment with nicorandil (10 mg/kg) 2 h prior to induction of IRI improved renal function, attenuated tubule damage, and prevented apoptosis of tubule cells, infiltration of neutrophils and macrophages, and production of inflammatory cytokines interleukin (IL)-6, IL-17 and tumour necrosis factor-α."( Nicorandil protects against ischaemia-reperfusion injury in newborn rat kidney.
Tian, ZL; Yao, L; Zhang, AQ; Zhang, YJ; Zhao, XX, 2013
)
2.16
"Pretreatment with nicorandil, a KATP channel opener, could attenuate OGD-induced BV-2 cells activation and inhibit pro-inflammatory factors release."( Nicorandil inhibits inflammasome activation and Toll-like receptor-4 signal transduction to protect against oxygen-glucose deprivation-induced inflammation in BV-2 cells.
Dong, YF; Gu, J; Liu, W; Sun, XL; Zhao, AP, 2014
)
2.17
"Treatment with nicorandil, clinidipine and GSPE was shown to significantly improve memory performance, attenuate oxidative damage and enhance AChE activity in rats."( The role of multifunctional drug therapy as an antidote to combat experimental subacute neurotoxicity induced by organophosphate pesticides.
Kaur, S; Majeed, AB; Mani, V; Ming, LC; Prakash, A; Singh, S, 2016
)
0.77
"Pretreatment with nicorandil could remarkably upregulate miR-7, depress the ER-related protein expressions including glucose-regulated protein 78 (GRP78), C/EBP-homologous protein (CHOP), and Caspase-12, and thereby attenuate inflammatory responses and astrocytic damages."( Potential role of microRNA-7 in the anti-neuroinflammation effects of nicorandil in astrocytes induced by oxygen-glucose deprivation.
Chen, ZZ; Dong, YF; Ji, J; Sun, XL; Yan, H; Yang, DD; Zhao, Z, 2016
)
0.99
"Treatment with nicorandil reduced the number of deaths from all causes to a similar extent with or without treatment with sulfonylureas."( Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study.
Horinaka, S; Ishimitsu, T; Kohro, T; Nagai, R; Suzuki, S; Yabe, A; Yagi, H; Yamazaki, T, 2010
)
1.09
"Late treatment with nicorandil for the established PAH was also effective in suppressing the additional progression of PAH."( Nicorandil attenuates monocrotaline-induced vascular endothelial damage and pulmonary arterial hypertension.
Hirata, Y; Morita, T; Nagai, R; Sahara, M; Sata, M, 2012
)
2.14
"Pretreatment with nicorandil for 6 days before imaging did not reduce LV dilation or improve function compared with those in control animals with identical infarction size."( Left ventricular remodeling after infarction: sequential MR imaging with oral nicorandil therapy in rat model.
Chujo, M; Higgins, CB; Krombach, GA; Lund, GK; Saeed, M; Watzinger, N; Wendland, MF, 2002
)
0.87
"Pretreatment with Nicorandil (2.5 mg kg(-1) daily, p.o.) and Amlodipine (5.0 mg kg(-1) daily, p.o.) for 3 days significantly prevented these alterations and restored the enzyme activities to near normal."( Synergistic effect of Nicorandil and Amlodipine on tissue defense system during experimental myocardial infarction in rats.
Devaki, T; Ebenezar, KK; Sathish, V, 2003
)
0.96
"Pretreatment with nicorandil (2.5 mg kg(-1) daily, p.o.) and amlodipine (5.0 mg kg(-1) daily, p.o.) for 3 d significantly prevented these alterations and restored the enzyme activity to near normal."( Synergistic effect of nicorandil and amlodipine on lysosomal hydrolases during experimental myocardial infarction in rats.
Devaki, T; Ebenezar, KK; Sathish, V, 2003
)
0.96
"Pretreatment with nicorandil (2.5 mg kg(-1) daily, p.o.) and amlodipine (5.0 mg kg(-1) daily, p.o.) for 3 days significantly prevented these alterations and restored the mitochondrial respiration and mitochondrial lipid contents to near normal."( Biochemical changes on the cardioprotective effect of nicorandil and amlodipine during experimental myocardial infarction in rats.
Devaki, T; Ebenezar, KK; Sathish, V, 2003
)
0.89
"Late treatment with nicorandil did not palliate established pulmonary arterial hypertension nor improved survival."( Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats.
Hongo, M; Ikeda, U; Kinoshita, O; Koizumi, T; Mawatari, E; Ruan, Z; Sakai, A; Shibamoto, T; Terasawa, F; Yazaki, Y, 2005
)
1.03
"Pretreatment with nicorandil concentration-dependently enhanced the cardioprotective effect of hypothermic high K+ cardioplegia. "( The risk of myocardial stunning is decreased concentration-dependently by KATP channel activation with nicorandil before high K+ cardioplegia.
Dawodu, AA; Iwashiro, K; Monti, F; Puddu, PE; Schiariti, M; Sugimoto, S, 1995
)
0.84
"Pretreatment with nicorandil 3 x 10(-7) and 3 x 10(-6) M potentiated the relaxation induced by ISO."( Potentiating effect of nicorandil, an antianginal agent, on relaxation induced by isoproterenol in isolated rat aorta: involvement of cyclic GMP-inhibitable cyclic AMP phosphodiesterase.
Inoue, M; Morikawa, M; Satake, N; Shibata, S; Zhou, Q, 1995
)
0.93
"Pretreatment with nicorandil and glyceryl trinitrate caused a marked reduction in myocardial infarct size expressed as percent of the area at risk [NC/pre group, 7.8(SEM 1.6)%; GTN/pre group, 11.9(2.3)%; control group, 31.0(5.6)%]. "( Effects of nicorandil and glyceryl trinitrate on infarct size, adenosine release, and neutrophil infiltration in the dog.
Gross, GJ; Mizumura, T; Nithipatikom, K, 1995
)
1.01
"Pretreatment with nicorandil (30-100 micrograms kg-1) accelerated the recovery of PSR potentials after spinal cord ischaemia."( Effects of nicorandil on the recovery of reflex potentials after spinal cord ischaemia in cats.
Moriya, H; Nakaya, H; Nemoto, T; Sekikawa, T; Suzuki, T, 1995
)
1
"Treatment with nicorandil for 4 weeks markedly reduced the relaxant effect of nicorandil itself and other vasodilators including sodium nitroprusside, nitric oxide, endothelium-derived relaxing factor released by carbachol, 8-Br-cyclic guanosine 3',5'-monophosphate (cGMP), a K+ channel opener, levcromakalim, and forskolin."( Effects of chronic oral administration of a high dose of nicorandil on in vitro contractility of rat arterial smooth muscle.
Karaki, H; Mitsui-Saito, M; Ozaki, H; Trongvanichnam, K, 1996
)
0.88
"Late treatment with nicorandil had no effect on infarct size (43.5 +/- 3.4%)."( Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo.
Baxter, GF; Imagawa, J; Yellon, DM, 1998
)
0.89
"Pretreatment with nicorandil and d-sotalol had no effects on the magnitude or recovery course of atrial ERP shortening after pacing."( Change of atrial refractory period after short duration of rapid atrial pacing: regional differences and possible mechanisms.
Chang, MS; Chen, SA; Cheng, JJ; Hung, CR; Kaun, P; Lee, SH; Lin, FY; Yu, WC, 1999
)
0.63
"Treatment with nicorandil improved the patient's cardiac function."( Stunned myocardium after hip arthroplasty.
Horita, Y; Mizogami, M; Shimo, K; Taguchi, T, 2000
)
0.65
"Pretreatment with nicorandil decreased the contraction."( 5-hydroxytryptamine induces vasoconstriction of the human umbilical artery: effects of hypoxia and nicorandil.
Tiritilli, A, 2000
)
0.85
"Pretreatment with nicorandil also improved functional recovery of the heart following preservation."( Ischemic preconditioning and nicorandil pretreatment improve donor heart preservation.
Kaneda, T; Ku, K; Oku, H; Otaki, M; Zhang, ZW, 2001
)
0.93
"Pretreatment with nicorandil may result in protection against reperfusion-induced arrhythmias and increased survival in anesthetized rabbits."( Effects of nicorandil administration on survival rate and arrhythmias during reperfusion in anesthetized rabbits.
Das, B; Karanth, KS; Sarkar, C, 2001
)
1.02

Toxicity

Nicorandil IC bolus injection is a simple, safe and effective hyperaemic method for FFR measurement and can be used as a substitute for adenosine.

ExcerptReferenceRelevance
"The aim was to evaluate the effective and safe dosage for intracoronary administration of nicorandil (2-nicotinamidoethyl nitrate) in dogs."( Determination of effective and safe dose for intracoronary administration of nicorandil in dogs.
Ishikawa, S; Kojima, S; Mori, H; Ohsawa, K, 1990
)
0.73
" Larger doses of the agent showed adverse effects depending on the dosages."( Determination of effective and safe dose for intracoronary administration of nicorandil in dogs.
Ishikawa, S; Kojima, S; Mori, H; Ohsawa, K, 1990
)
0.51
" The most often reported adverse event was headache, which was responsible for most of the study withdrawals due to clinical intolerance (9."( Nicorandil safety in the long-term treatment of coronary heart disease.
Darmon, JY; Witchitz, S, 1995
)
1.73
" Adverse events usually occurred early in the course of treatment."( Safety profile of an anti-anginal agent with potassium channel opening activity: an overview.
Roland, E, 1993
)
0.29
" These results indicate that dilatation of the epicardial coronary artery was achieved with intracoronary nicorandil in a dose-dependent manner (up to 1 mg over 1 min) without any adverse effects in man, and the dilatory effect on coronary resistance vessels was of short duration."( Effective and safe dose of intracoronary nicorandil in man.
Fujita, M; Igawa, A; Inouc, H; Miwa, K; Yamanishi, K, 1995
)
0.77
" Although the total numbers of adverse events with each antianginal drug were similar, heart rate and blood pressure were significantly decreased by calcium antagonists but not changed by nicorandil (8."( [Systematic review on the short-term efficacy and safety of nicorandil for stable angina pectoris in comparison with those of β-blockers, nitrates and calcium antagonists].
Hanai, Y; Hishinuma, S; Mita, M; Shoji, M, 2010
)
0.79
" Incidents of adverse cardiac drug reactions are more common in patients with preexisting heart disease than the general population."( Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Bers, DM; Diecke, S; Gong, T; Knowles, JW; Lan, F; Lee, AS; Liang, P; Nguyen, PK; Robbins, RC; Sallam, K; Sanchez-Freire, V; Wang, PJ; Wang, Y; Wu, JC, 2013
)
0.39
" Our data indicate that healthy and diseased individuals exhibit different susceptibilities to cardiotoxic drugs and that use of disease-specific hiPSC-CMs may predict adverse drug responses more accurately than the standard human ether-a-go-go-related gene test or healthy control hiPSC-CM/hESC-CM screening assays."( Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Bers, DM; Diecke, S; Gong, T; Knowles, JW; Lan, F; Lee, AS; Liang, P; Nguyen, PK; Robbins, RC; Sallam, K; Sanchez-Freire, V; Wang, PJ; Wang, Y; Wu, JC, 2013
)
0.39
" Its use is limited by a major side effect of cardiotoxicity."( Cardioprotective effects of nicorandil, a mitochondrial potassium channel opener against doxorubicin-induced cardiotoxicity in rats.
Abdel-Raheem, IT; Abouzied, MM; Taye, A, 2013
)
0.68
" The benefits and adverse events were assessed during acute phase and 12-month follow-up period."( Safety and feasibility of high-dose administration of nicorandil before reperfusion therapy in acute myocardial infarction.
Horiuchi, M; Miura, S; Murasato, Y; Saku, K; Suematsu, Y; Takata, K; Yamamoto, T, 2013
)
0.64
" Although adenosine triphosphate (ATP) is generally used as the hyperemic stimulus, we sometimes encounter adverse events like hypotension during FFR measurement."( Feasibility and safety of intracoronary nicorandil infusion as a novel hyperemic agent for fractional flow reserve measurements.
Amano, T; Ando, H; Fujimoto, M; Kato, D; Kosaka, T; Kuhara, Y; Kumagai, S; Kurita, A; Kuroda, Y; Maeda, K; Mizuno, T; Sakurai, S; Sato, S; Suzuki, A; Takashima, H; Toda, Y; Waseda, K; Watanabe, A, 2015
)
0.68
" Therefore, determining an efficient and safe method to achieve hyperemia is important for evaluating FFR."( Usefulness and safety of intracoronary administration of nicorandil for evaluating fractional flow reserve in Japanese patients.
Ishihara, H; Kawakami, T; Ono, H; Takahashi, Y; Tanaka, N, 2015
)
0.66
"Intracoronary nicorandil administration is more useful than and as safe as intravenous administration of ATP for evaluating FFR in Japanese patients."( Usefulness and safety of intracoronary administration of nicorandil for evaluating fractional flow reserve in Japanese patients.
Ishihara, H; Kawakami, T; Ono, H; Takahashi, Y; Tanaka, N, 2015
)
1.02
"Nicorandil IC bolus injection is a simple, safe and effective hyperaemic method for FFR measurement and can be used as a substitute for adenosine."( Safety and efficacy of intracoronary nicorandil as hyperaemic agent for invasive physiological assessment: a patient-level pooled analysis.
Amano, T; Doh, JH; Ishihara, H; Kato, D; Koo, BK; Kurita, A; Lee, JM; Lim, WH; Nam, CW; Oi, M; Takashima, H; Tanaka, N; Toyofuku, M; Waseda, K, 2016
)
2.15
" Adverse events were registered in 10 of 61 and 7 of 59 patients (16."( [Comparative Assessment of Antianginal Efficacy and Safety of Nicorandil at the Background of Therapy With -Adrenoblockers in Ischemic Heart Disease Patients With Stable Angina].
Deev On Behalf Of The Kvazar Study, AD; Kutishenko, NP; Martsevitch, SY, 2016
)
0.67
" The secondary outcome was the incidence of major adverse cardiac events (MACE), which was a composite of cardiac death, nonfatal myocardial infarction, new heart failure or coronary revascularization."( Efficacy and safety of nicorandil on perioperative myocardial injury in patients undergoing elective percutaneous coronary intervention: results of the PENMIPCI trial.
Li, L; Long, M; Lu, H; Su, Q; Ye, Z, 2018
)
0.79
" The secondary outcomes were major adverse events, including mortality, heart failure, recurrent myocardial infarction, stroke, and renal replacement therapy."( Efficacy and Safety of Nicorandil in Preventing Contrast-Induced Nephropathy after Elective Percutaneous Coronary Intervention: A Pooled Analysis of 1229 Patients.
Chen, X; Jiang, Y; Luo, J; Mo, S; Rong, J; Yi, B; Yi, D, 2020
)
0.87
"Our article indicated that nicorandil could prevent CIN without increasing the major adverse events."( Efficacy and Safety of Nicorandil in Preventing Contrast-Induced Nephropathy after Elective Percutaneous Coronary Intervention: A Pooled Analysis of 1229 Patients.
Chen, X; Jiang, Y; Luo, J; Mo, S; Rong, J; Yi, B; Yi, D, 2020
)
1.17
"We analyzed the clinical data of patients including the incidence of periprocedural myocardial injury (PMI) and major adverse cardiovascular events (MACE) from selected articles."( The Efficacy and Safety of Nicorandil for Periprocedural Myocardial Injury in Patients Undergoing PCI: A Meta-Analysis.
Hu, W; Lu, Y; Song, Q; Wang, Q, 2020
)
0.86
" Dyspnoea severity, the ratio of E to e' (E/e'), the incidence of side effects and adverse events, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, left ventricular ejection fraction (LVEF; left ventricular systolic function) before discharge, average length of hospitalisation, LVEF and soluble suppression of tumorigenicity-2 (sST2) at 3 months after discharge, incidence of major adverse cardiac and cerebrovascular events (MACCE) and readmission rate within 3 months were recorded and compared between the two groups."( Effectiveness and Safety of Intravenous Nicorandil Application in Patients With Acute Heart Failure With Low Baseline Blood Pressure.
Cai, Z; Ke, S; Ke, X; Qiu, W; Wu, Y; Zhang, Y, 2022
)
0.99
"Doxorubicin-induced cardiotoxicity (DIC) is a common side effect of doxorubicin chemotherapy, and a major mechanism of DIC is inflammation."( Nicorandil Ameliorates Doxorubicin-Induced Cardiotoxicity in Rats, as Evaluated by 7 T Cardiovascular Magnetic Resonance Imaging.
Gao, F; He, B; Huang, R; Ma, L; Wan, Y; Wang, C; Wang, L; Wang, S; Zhang, M; Zhu, D, 2023
)
2.35
" the safety outcomes included the incidence of hypotension after drug infusion and other adverse events during medication."( Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial.
Gao, W; Ge, J; Huang, D; Ma, Y; Qian, J; Wu, H; Zhong, X; Zhou, J, 2022
)
1.1
"CLEAN will determine whether the addition of intravenous nicorandil as adjuncts to reperfusion therapy reduces the major adverse cardiovascular events in STEMI patients undergoing primary PCI."( Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial.
Gao, W; Ge, J; Huang, D; Ma, Y; Qian, J; Wu, H; Zhong, X; Zhou, J, 2022
)
1.35

Pharmacokinetics

Nicorandil (NIC) was combined with the beta-adrenergic receptor antagonists propranolol (PRO) and atenolol (ATN) and with the calcium channel blocker diltiazem (DTZ) to determine their cardiovascular and pharmacokinetic interactions. Pharmacokinetic parameters of nicorandIL and its isomers, as well as plasma concentrations of the corresponding denitrated metabolites and also nicotinamide and nitrite were determined.

ExcerptReferenceRelevance
" On average, the Cmax then is approximately 300 ng/ml, which is achieved rapidly within 30 min after drug intake."( Pharmacokinetic profile of nicorandil in humans: an overview.
Frydman, A, 1992
)
0.58
" No significant difference was noted in any of the other pharmacokinetic parameters examined in the three groups, not even on comparing values obtained on the first and last days of treatment."( Pharmacokinetics of nicorandil in patients with normal and impaired renal function.
Molinaro, M; Regazzi, MB; Rondanelli, R; Salvadeo, A; Sartirana, E; Segagni, S; Villa, G, 1992
)
0.61
" The utility of the method is demonstrated in a dog pharmacokinetic study in which a 5-mg intravenous dose was compared to a 10-mg oral solution dose in six beagle dogs."( Determination of nicorandil in plasma using high-performance liquid chromatography with photoconductivity and ultraviolet detection. Application to pre-clinical pharmacokinetics in beagle dogs.
Lewis, RC; Schwende, FJ, 1990
)
0.62
" Nicorandil plasma concentrations increased disproportionately with dose, but nicorandil elimination obeyed apparent monoexponential kinetics, and the apparent half-life (t1/2) increased with dose."( A modified product inhibition model describes the nonlinear pharmacokinetics of nicorandil in rats.
Bachert, EL; Chung, SJ; Fung, HL; Li, ZW; Zhao, L, 1994
)
1.43
"In support of clinical antianginal studies, the vasodilator nicorandil (NIC) was combined with the beta-adrenergic receptor antagonists propranolol (PRO) and atenolol (ATN) and with the calcium channel blocker diltiazem (DTZ) to determine their cardiovascular and pharmacokinetic interactions."( Cardiovascular and pharmacokinetic interactions between nicorandil and adjunctive propranolol, atenolol or diltiazem in conscious dogs.
Humphrey, SJ, 1998
)
0.79
" The interaction observed appears to be pharmacodynamic at the receptor level as expected."( Influence of nicorandil on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits.
Kilari, EK; Satyanarayana, S, 2006
)
0.7
" PAWP was used as the pharmacodynamic variable."( Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure.
Holford, NH; Iida, S; Kinoshita, H, 2008
)
0.58
" The validated method was successfully applied to a pharmacokinetic study after per os administration of nicorandil in rats."( Simultaneous quantitation of nicorandil and its denitrated metabolite in plasma by LC-MS/MS: application for a pharmacokinetic study.
Araujo, DP; Bastos, LF; César, IC; Coelho, Mde M; de Fátima, Â; Godin, AM; Guidine, PA; Pianetti, GA, 2011
)
0.87
" Pharmacokinetic parameters of nicorandil and its isomers, as well as the plasma concentrations of the corresponding denitrated metabolites and also nicotinamide and nitrite were determined."( Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
Almeida, MO; Araujo, DP; César, IC; Coelho, MM; de Fátima, A; Dutra, MM; Godin, AM; Machado, RR; Menezes, RR; Oliveira, FC; Pianetti, GA; Santos, DA; Santos, JR, 2014
)
0.92

Compound-Compound Interactions

Nicorandil in combination with trimetazidine can be considered as an effective and potential treatment strategy in reducing the rate of MACE in patients with CHD in the Chinese population.

ExcerptReferenceRelevance
"To study the protective effect of mitochondrial ATP-sensitive K(+) channel (mitoK(ATP) channel) opener, nicorandil, combined with Na(+)/Ca(2+) exchange blocker KB-R7943 on myocardial ischemia-reperfusion injury in isolated rat hearts; the isolated rat heart was perfused by modified Langendorff device, after 15-min balanced perfusion, 45-min ischemia (about left and right coronary perfusion flow reduced to 5% of the original irrigation flow), and 2-h reperfusion were performed."( The protective effect of mitochondrial ATP-sensitive K+ channel opener, nicorandil, combined with Na+/Ca2+ exchange blocker KB-R7943 on myocardial ischemia-reperfusion injury in rat.
Jia, D, 2011
)
0.82
"Nicorandil in combination with trimetazidine can be considered as an effective and potential treatment strategy in reducing the rate of MACE in patients with CHD in the Chinese population."( Clinical Implications of Nicorandil Combined with Trimetazidine in Patients with Coronary Heart Disease: A Real-World Observational Study.
Li, N; Liu, J; Qiu, L; Shen, L; Shu, H; Zhou, N, 2022
)
2.47
" This article mainly studies the analysis of no-reflow in patients with acute ST-segment elevation myocardial infarction after PCI and the effect of coronary nicorandil on CoO nanoparticles combined with MRI."( CoO Nanoparticles Combined with MRI: Analysis of No-Reflow in Patients with Acute ST-Segment Elevation Myocardial Infarction after PCI and the Effect of Coronary Nicorandil.
Li, P; Li, Y; Liang, X; Liao, W; Lin, Z; Liu, M; Xie, W, 2022
)
1.11
" I-Post combined with nicorandil showed better therapeutic effects in diabetic I/R rats, and the combined treatment further reduced the area of myocardial injury in diabetic I/R rats compared with I-Post or nicorandil treatment alone (P < 0."( Protective effect of ischaemic postconditioning combined with nicorandil on myocardial ischaemia‒reperfusion injury in diabetic rats.
Chen, B; Lian, Z; Ren, J; Wan, Q; Wang, Y; Xia, Z; Yang, Y; Yao, X; Zhou, C, 2022
)
1.28
"I-Post combined with nicorandil treatment maintains effective cardioprotection against diabetic myocardial I/R injury by activating the PI3K/Akt signalling pathway."( Protective effect of ischaemic postconditioning combined with nicorandil on myocardial ischaemia‒reperfusion injury in diabetic rats.
Chen, B; Lian, Z; Ren, J; Wan, Q; Wang, Y; Xia, Z; Yang, Y; Yao, X; Zhou, C, 2022
)
1.28

Bioavailability

Nicorandil prevents paclitaxel-induced endothelial dysfunction, which may be brought by improved NO bioavailability due to the reduction of oxidative stress via K(ATP) channel activation.

ExcerptReferenceRelevance
" Thus, it easily enters the systemic blood flow, resulting in almost complete bioavailability (75-100%)."( Pharmacokinetic profile of nicorandil in humans: an overview.
Frydman, A, 1992
)
0.58
"To evaluate the bioavailability of 4 different formulations of nicorandil, 10 mg and 20 mg (Bracco) versus 10 mg ang 20 mg (Merck), we have carried out a study involving 24 young healthy volunteers."( [The bioavailability of nicorandil after oral administration of a single dose of 10 or 20 mg preparations].
Buggia, I; Iacona, I; Molinaro, M; Regazzi, MB; Rondanelli, R; Villani, P; Zoia, C, 1992
)
0.83
" The absolute bioavailability of nicorandil in dogs in this study was determined to be 84."( Determination of nicorandil in plasma using high-performance liquid chromatography with photoconductivity and ultraviolet detection. Application to pre-clinical pharmacokinetics in beagle dogs.
Lewis, RC; Schwende, FJ, 1990
)
0.9
" Individual plasma nicorandil concentrations were variable and systemic bioavailability was reduced compared with values reported in healthy subjects."( Dose-related haemodynamic effects and pharmacokinetics of oral nicorandil in patients evaluated for chest pain.
Arnold, JM; Hearron, AE; Jungbluth, GL; Kowey, PR; Luderer, JR; Wolf, DL, 1994
)
0.86
"To improve the bioavailability and taste of fast-disintegrating tablet (FD tablet) containing nicorandil-loaded particles."( [Pharmaceutical evaluation of fast-disintegrant tablet containing nicorandil-loaded particles].
Jin, Y; Morimoto, Y; Natsume, H; Ohkuma, H; Sugibayashi, K; Wang, CF, 2001
)
0.77
" However pharmacokinetics parameters of nicorandil after oral administration of FD tablet containing nicorandil-loaded particles showed that nicorandil was delivered into the body at a suitable absorption rate with similar AUC, delayed Tmax and lower Cmax."( [Pharmaceutical evaluation of fast-disintegrant tablet containing nicorandil-loaded particles].
Jin, Y; Morimoto, Y; Natsume, H; Ohkuma, H; Sugibayashi, K; Wang, CF, 2001
)
0.82
"The reports suggest that the modification of properties of myristyl alcohol and stearyl alcohol released from the drug-loaded particles system would lead to more acceptable bioavailability of the system."( [Pharmaceutical evaluation of fast-disintegrant tablet containing nicorandil-loaded particles].
Jin, Y; Morimoto, Y; Natsume, H; Ohkuma, H; Sugibayashi, K; Wang, CF, 2001
)
0.55
" The resultant sandwich was heat-sealed to produce circle-shaped TTS (20 cm2) that were subjected to bioavailability study in human volunteers against immediate release nicorandil tablet."( Bioavailability of nerodilol-based transdermal therapeutic system of nicorandil in human volunteers.
Al-Saidan, SM; Chandrasekhar, DV; Krishnaiah, YS; Satyanarayana, V, 2005
)
0.76
" In conclusion, nicorandil prevents paclitaxel-induced endothelial dysfunction, which may be brought by improved NO bioavailability due to the reduction of oxidative stress via K(ATP) channel activation."( Paclitaxel-induced endothelial dysfunction in living rats is prevented by nicorandil via reduction of oxidative stress.
Aizawa, K; Ishida, H; Ishizuka, N; Sekine, K; Serizawa, K; Suzuki, T; Takahari, Y; Tashiro, Y; Yogo, K, 2012
)
0.96
" It was reported that doxorubicin-induced cardiotoxicity is mediated through oxidative stress coupled with impaired NO bioavailability and NF-κB activation."( Cardioprotective effects of nicorandil, a mitochondrial potassium channel opener against doxorubicin-induced cardiotoxicity in rats.
Abdel-Raheem, IT; Abouzied, MM; Taye, A, 2013
)
0.68
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

This report presents the findings of some studies on single intravenous and oral dosing performed in healthy volunteers. Dose-response curves for the relaxing and cyclic guanosine monophosphate (cGMP) increasing effects of nicorandil were obtained in isolated strips of bovine coronary arteries and compared with those of other nitrovasodilatators.

ExcerptRelevanceReference
" Hemodynamic responses occurred within 5 min of dosing and terminated within 240 min."( Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans.
Giles, TD; Hearron, AE; Karalis, DG; Mohrland, JS; Pina, IL; Porter, RS; Quiroz, AC; Roffidal, L; Wolf, DL; Zaleski, R, 1992
)
0.53
" After 3 weeks, the dosage could be doubled according to clinical criteria."( Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study.
Bucx, JJ; Henneman, JA; Hugenholtz, PG; Kelder, JC; Kerker, JP; Meeter, K; Tijssen, JG, 1992
)
0.66
" There was no biostatistical agreement between the two methods in estimating cardiovascular function either before or after dosing (ZCG estimated substantially larger SV, CO and lower TPR)."( Agreement and reproducibility of the estimates of cardiovascular function by impedance cardiography and M-mode echocardiography in healthy subjects.
Belz, GG; Butzer, R; de Mey, C; Matthews, J; Schroeter, V, 1992
)
0.28
" Phentolamine, antazoline, tolazoline, and midaglizole also shifted the dose-response curve for nicorandil to the right in the dose range of 1-100 microM."( Effects of imidazoline-related compounds on the mechanical response to nicorandil in the rat portal vein.
Ichihara, K; Nagasaka, M; Okumura, K, 1992
)
0.73
" In conclusion, whereas nicorandil possesses a dilatory action on both large and small coronary arteries, in a clinical setting, with a daily dosage of 15-30 mg, part of the beneficial effects of nicorandil may be the result of a dilation of the large coronary arteries and may be due to the fact that a coronary steal phenomenon does not occur after nicorandil administration."( Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs.
Hashimoto, K; Kinoshita, M; Ohbayashi, Y, 1991
)
0.91
"The aim was to evaluate the effective and safe dosage for intracoronary administration of nicorandil (2-nicotinamidoethyl nitrate) in dogs."( Determination of effective and safe dose for intracoronary administration of nicorandil in dogs.
Ishikawa, S; Kojima, S; Mori, H; Ohsawa, K, 1990
)
0.73
" Dose-response curves for the increase in coronary blood flow produced by nicorandil or cromakalim were shifted to the right in a parallel manner and to similar extents by glibenclamide given intravenously to support dogs."( Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism.
Satoh, K; Taira, N; Yoneyama, F, 1990
)
1.95
" Dose-response curves for the relaxing and cyclic guanosine monophosphate (cGMP) increasing effects of nicorandil were obtained in isolated strips of bovine coronary arteries and compared with those of other nitrovasodilatators."( Cyclic GMP in nicorandil-induced vasodilatation and tolerance development.
Holzmann, S; Kukovetz, WR, 1987
)
0.85
" The dose-response curve of nifedipine was shifted parallel to the right by the infusion of Bay K 8644 and the dose-ratio was the greatest of the 4 drugs."( Differential antagonism by Bay K 8644 of vasodilator effects of nifedipine, diltiazem, nicorandil and nitroglycerin in dog femoral circulation.
Ishii, K; Sato, Y; Taira, N, 1988
)
0.5
"This report presents the findings of some studies on single intravenous and oral dosing performed in healthy volunteers to determine the pharmacokinetics and preliminary metabolism of nicorandil, a new vasodilator acting via increase of both membrane potassium conductance and intracellular cyclic guanosine monophosphate in vascular smooth muscle."( Pharmacokinetics of nicorandil.
Bouthier, J; Bruno, R; Caplain, H; Chapelle, P; Diekmann, H; Frydman, AM; Gaillard, C; Le Liboux, A; Thebault, JJ; Ungethuem, W, 1989
)
0.79
" Nicorandil administration produced a significant decrease in systolic and diastolic blood pressure, from 18 minutes after dosing which lasted up to the end of the study (i."( Effects of nicorandil on arterial and venous vessels of the forearm in systemic hypertension.
Bouthier, J; Chau, NP; Levenson, J; Roland, E; Simon, AC, 1989
)
1.58
" Maximal hemodynamic changes were observed 30 minutes after dosing and remained statistically significant at 3 hours."( Hemodynamic action of nicorandil in chronic congestive heart failure.
Bouthier, J; Dahan, M; Gourgon, R; Jaeger, P; Juliard, JM; Solal, AC, 1989
)
0.59
" NE- and KCI-induced dose-response relationships were differentially depressed by SG-75 (NE much greater than KCI) and NIF (KCI much greater than NE)."( Effects of 2-nicotinamidoethyl nitrate on agonist-sensitive Ca++ release and Ca++ entry in rabbit aorta.
Hester, RK, 1985
)
0.27
" Dose-response relations with regard to guanylate cyclase stimulation of organic nitrates and sodium nitrite were compared in the presence of cysteine and its closely related methylester."( Guanylate cyclase activation by organic nitrates is not mediated via nitrite.
Kukovetz, WR; Romanin, C, 1988
)
0.27
" To measure the dose-response kinetics of bolus injections of intracoronary nicorandil and to compare the vasodilatory response to nicorandil with that of intracoronary papaverine in humans, coronary blood flow velocity was measured in 30 patients using a 3Fr intravascular Doppler catheter."( Coronary microvascular response to intracoronary administration of nicorandil.
Hongo, M; Nakatsuka, T; Sekiguchi, M; Takenaka, H; Uchikawa, S; Watanabe, N, 1995
)
0.76
" Employing additional short term infusions, dose-response curves were obtained by giving nicorandil or glyceryl trinitrate at increasing dosages both in the preinfusion control state and 4 h after terminating the nicorandil infusion."( Long term increases in coronary arterial conductance during five day infusion of low dose nicorandil.
Bassenge, E; Fink, B; Huckstorf, C; Sommer, O, 1994
)
0.73
" However, at the higher dose there was a shift of the dose-response curve of both nicorandil and glyceryl trinitrate to the right, indicating some tolerance."( Long term increases in coronary arterial conductance during five day infusion of low dose nicorandil.
Bassenge, E; Fink, B; Huckstorf, C; Sommer, O, 1994
)
0.74
" In healthy volunteers and at this dosage (10 mg twice a day), cross tolerance between nicorandil and nitroglycerin does not occur."( Comparison of tolerance to intravenous nitroglycerin during nicorandil and intermittent nitroglycerin patch in healthy volunteers.
Billon, N; Funck-Brentano, C; Jaillon, P; Tabone, X, 1994
)
0.75
" The dose-response relation between ATP and the UDP-induced KATP-channel activity was shifted to the right in the presence of Mg2+ (2 mM)."( Regulation of ATP-sensitive K+ channels by ATP and nucleotide diphosphate in rabbit portal vein.
Kamouchi, M; Kitamura, K, 1994
)
0.29
" Particular attention was focused on the aspects of dose-response relationship, temperature sensitivity, and ischemic tolerance."( Effect of the potassium-channel opener nicorandil as an adjunct to cardioplegia on myocardial preservation in isolated rabbit hearts.
Sunamori, M; Wang, Y; Yoshida, T, 1996
)
0.56
" When dosed orally JTV-506 (0."( Effect of JTV-506, a novel vasodilator, on coronary blood flow in conscious dogs.
Aisaka, K; Hirata, Y, 1997
)
0.3
" At every dose level, rSO2 and BVI were determined, and the dose-response relationship was obtained."( [Effects of nicorandil on regional cerebral oxygen saturation].
Dohi, S; Kasuya, Y, 1997
)
0.68
" Nicorandil (3 mg/kg) given orally was rapidly absorbed, reaching the maximal plasma (approximately 2,600 ng/ml) and vascular concentrations (approximately 176 ng/g) at 15 min after the dosing and thereafter decreased rapidly."( Vascular levels and cGMP-increasing effects of nicorandil administered orally to rats.
Akima, M; Kamachi, S; Kitajima, S; Moriyasu, M; Sakai, K; Tanikawa, M, 1998
)
1.47
" Nicorandil (100 micrograms kg-1 bolus, 25 micrograms kg-1 min-1 infusion) was begun and a second dose-response study of isoflurane was obtained as before."( Cardiovascular effects of concomitant administration of isoflurane and nicorandil in dogs.
Bastien, O; Foëx, P; Pigott, D; Piriou, V; Ross, S; Trivin, F, 1998
)
1.44
"This study reports subcellular localization of nicorandil in the myocardium and metabolism in mitochondria after oral dosing of 3 mg/kg nicorandil to rats."( Myocardial distribution and biotransformation in vitro and in vivo of nicorandil in rats, with special reference to mitochondria.
Hamada, H; Kitajima, S; Sakai, K; Tsuchiya, Y, 1999
)
0.79
" Dose-response relationships to the KATP channel agonist nicorandil were established in each dog using doses (25, 50, and 100 microg/min) previously shown to increase coronary collateral blood flow."( Sevoflurane selectively increases coronary collateral blood flow independent of KATP channels in vivo.
Hettrick, DA; Kersten, JR; Pagel, PS; Schmeling, T; Tessmer, J; Warltier, DC, 1999
)
0.55
" Electron-microscopic autoradiograms recorded 15min after oral dosing of 3 mg kg(-1) [3H]nicorandil to rats also showed the presence of silver grains generated by the radioactive nicorandil or its metabolites in the mitochondria of the heart."( Ultrastructural localization of nicorandil in the heart of rats.
Kitajima, S; Sakai, K; Tsuchiya, Y, 1998
)
0.81
" We prospectively used 12-lead electrocardiograms and echocardiograms to study 52 consecutive menopausal patients with syndrome X (group subdivided into subgroup 1a, 32 patients who received nicorandil, an adenosine triphosphate-sensitive potassium ion channel opener; subgroup 1b, 20 patients without dosing nicorandil)."( Effect of estrogen on ventricular repolarization in menopausal patients with syndrome X and effects of nicorandil.
Lee, TM; Lee, YT; Su, SF; Tsai, CH, 1999
)
0.71
" Pooled dose-response data confirm that nicorandil concentrations as low as 10 micromol/liter turn on mitoK(ATP) channels, while surfaceK(ATP) current requires exposure to millimolar concentrations."( Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels.
Marbán, E; O'Rourke, B; Sasaki, N; Sato, T, 2000
)
2.02
"A simple, fast, precise, specific and economical reverse phase liquid chromatographic method was developed for determination of nitrate (NIT) impurity from nicorandil (NIC) and its tablet dosage form."( Determination of inorganic nitrate impurity from nicorandil and its tablet dosage form by simple reversed phase liquid chromatographic method.
Gadhvi, MP; Mehta, TN; Subbaiah, G, 2006
)
0.79
" In Group MNG, the dose-response curve shifted back to the right and the ED50 for inducing paraparesis was 11."( Intrathecal nicorandil and small-dose morphine can induce spastic paraparesis after a noninjurious interval of spinal cord ischemia in the rat.
Fuchigami, T; Kakinohana, M; Murata, K; Nakamura, S; Sugahara, K, 2006
)
0.71
" Patients were stratified based on status of nicorandil treatment before PCI, as follows: patients receiving nicorandil 5 mg PO TID (the recommended dosage in Japan) for >1 month before PCI (nicorandil group) or those who did not receive nicorandil (control group)."( Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis.
Aoyama, T; Ichimiya, S; Ishii, H; Kanashiro, M; Kasuga, H; Maruyama, S; Matsubara, T; Matsuo, S; Mitsuhashi, H; Murohara, T; Naruse, K; Takahashi, H; Toriyama, T; Yamada, S, 2007
)
0.94
"The aims of the study were 1) to evaluate the pharmacokinetics of nicorandil in healthy subjects and acute heart failure (AHF) patients and 2) to evaluate the exposure-response relationship with pulmonary arterial wedge pressure (PAWP) in AHF patients and to predict an appropriate dosing regimen for nicorandil."( Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure.
Holford, NH; Iida, S; Kinoshita, H, 2008
)
0.81
" We hypothesised that in the case of high-dosage nicorandil or after an increased dosage of nicorandil, nicotinic acid and nicotinamide (two main metabolites of nicorandil) cannot appropriately merge into the endogenous pool of nicotinamide adenine dinucleotide/phosphate, which leads to abnormal distribution of these metabolites in the body."( Role of nicotinic acid and nicotinamide in nicorandil-induced ulcerations: from hypothesis to demonstration.
Barbaud, A; Brouillard, C; Cuny, JF; Gauchotte, G; Jouzeau, JY; Petitpain, N; Scala-Bertola, J; Schmutz, JL; Trechot, P, 2015
)
0.93
" Nicorandil was administered at a dosage of 15 mg/kg/day by gavage feeding."( Nicorandil attenuates endothelial VCAM-1 expression via thioredoxin production in diabetic rats induced by streptozotocin.
Li, Y; Liu, L; Liu, Y; Qi, B; Wang, Z; Wu, Q, 2014
)
2.76
" Thus an attempt was made to develop a single preparative method for isolation and HPLC and UPLC methods for identification of impurities of nicorandil in tablet dosage form."( Preparative isolation and high-resolution mass identification of 10 stressed study degradants of nicorandil tablets.
Malipeddi, H; Prakash, L; Subbaiah, BV, 2015
)
0.84
" It is also necessary to ensure that a dosing regime is followed that avoids nitrate tolerance, which not only results in loss of drug efficacy, but might also cause endothelial dysfunction and increase long-term cardiovascular risk."( Vasodilator Therapy: Nitrates and Nicorandil.
Kaski, JC; Tarkin, JM, 2016
)
0.71
" Our study demonstrates that a 30 mg/kg dosing schedule of nicorandil increases tissue survival in the zone of stasis by attenuating ischemia-reperfusion injury."( Nicorandil reduces burn wound progression by enhancing skin blood flow.
Choi, J; Chung, HY; Jeong, W; Kim, J; Kim, R; Lee, HW; Park, SW, 2018
)
2.17
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
vasodilator agentA drug used to cause dilation of the blood vessels.
potassium channel openerA potassium channel modulator that opens the potassium channel.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyridinecarboxamideA member of the class of pyridines that is a substituted pyridine in which at least one of the substituents is a carboxamide or N-substituted caraboxamide group.
nitrate esterAny member of the class of nitrates resulting from the esterification of nitric acid with an alcohol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency19.95260.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency19.95260.025120.237639.8107AID893
15-lipoxygenase, partialHomo sapiens (human)Potency19.95260.012610.691788.5700AID887
RAR-related orphan receptor gammaMus musculus (house mouse)Potency1.18830.006038.004119,952.5996AID1159521
SMAD family member 2Homo sapiens (human)Potency3.79020.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency3.79020.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency30.73370.000714.592883.7951AID1259369; AID1259392
EWS/FLI fusion proteinHomo sapiens (human)Potency33.59770.001310.157742.8575AID1259252; AID1259253; AID1259256
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency9.520519.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.00170.057821.109761.2679AID1159526
beta-2 adrenergic receptorHomo sapiens (human)Potency25.11890.00586.026332.6427AID492947
cytochrome P450 2C19 precursorHomo sapiens (human)Potency3.98110.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency1.99530.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency0.11580.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency20.31480.005612.367736.1254AID624032
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency1.99530.00638.235039.8107AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency7.07950.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (79)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1139135AUC (0 to infinity) in Swiss mouse at 100 mg/kg, po by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1139132Cmax in Swiss mouse at 100 mg/kg, po by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID167355Vasorelaxation activity in the isolated endothelium-denuded rabbit aorta1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID232773Selectivity index as the ratio of doses requires to induce a reduction in MABP and that required to prevent ECG changes.1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
AID1139122Antinociceptive activity in Swiss mouse assessed as inhibition of formaldehyde-induced nociceptive response in right hind paw at 100 to 150 mg/kg, po administered 1 hr followed by formaldehyde challenge measured 15 to 30 mins2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1139121Antinociceptive activity in po dosed Swiss mouse assessed as inhibition of formaldehyde-induced nociceptive response in right hind paw administered 1 hr followed by formaldehyde challenge measured over 5 mins2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1139156Drug metabolism in Swiss mouse plasma assessed as formation of nicotinamide at 100 mg/kg, po after 10 hrs by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1139136Half life in Swiss mouse at 100 mg/kg, po by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1139133Tmax in Swiss mouse at 100 mg/kg, po by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID178068Inhibition of methacholine-induced ECG changes in the anesthetized rat after intravenous administration.1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
AID234360Ratio of vasorelaxant effect on KCl-Induced contraction of rat aorta to that of porcine coronary artery1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and selective coronary vasodilatory activity of 3,4-dihydro-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol derivatives: novel potassium channel openers.
AID178994Inhibition of vasopressin-induced ECG changes in rat1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
AID227627Vasorelaxant effect on KCl-Induced contraction of rat aorta1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and selective coronary vasodilatory activity of 3,4-dihydro-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol derivatives: novel potassium channel openers.
AID1139129Antinociceptive activity in Swiss mouse assessed as inhibition of formaldehyde-induced nociceptive response in right hind paw at 100 mg/kg, po administered 1 hr followed by formaldehyde challenge measured for 15 to 30 mins2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1139128Antinociceptive activity in Swiss mouse assessed as inhibition of formaldehyde-induced nociceptive response in right hind paw at 100 mg/kg, po administered 1 hr followed by formaldehyde challenge measured over 5 mins2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID178069Inhibition of methacholine-induced ECG changes in the anesthetized rat after oral administration.1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
AID160680Vasorelaxant effect on KCl-Induced contraction of porcine coronary artery1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and selective coronary vasodilatory activity of 3,4-dihydro-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol derivatives: novel potassium channel openers.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1139130Toxicity in Swiss mouse assessed as time spent on rotating rod at 150 mg/kg, po administered 1 hr prior to testing (Rvb = 120 secs)2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID173808Concentration required to reduce mean arterial blood pressure in rat after intravenous administration.1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1139155Drug metabolism in Swiss mouse plasma assessed as nitrite level at 100 mg/kg, po measured after 0.25 to 3 hrs by Griess assay2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1139134AUC (0 to t) in Swiss mouse at 100 mg/kg, po by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID1139123Antinociceptive activity in Swiss mouse assessed as inhibition of formaldehyde-induced nociceptive response in right hind paw at 3 to 30 mg/kg, po administered 1 hr followed by formaldehyde challenge2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID493017Wombat Data for BeliefDocking1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346625Mouse Kir6.1 (Inwardly rectifying potassium channels)1997The Journal of physiology, Mar-15, Volume: 499 ( Pt 3)Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channel.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,427)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990168 (11.77)18.7374
1990's393 (27.54)18.2507
2000's409 (28.66)29.6817
2010's337 (23.62)24.3611
2020's120 (8.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 89.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index89.94 (24.57)
Research Supply Index7.44 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index163.97 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (89.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials207 (13.92%)5.53%
Reviews137 (9.21%)6.00%
Case Studies162 (10.89%)4.05%
Observational8 (0.54%)0.25%
Other973 (65.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (29)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT01331902]Phase 4200 participants (Anticipated)Interventional2011-03-31Recruiting
A Clinical Trial to Assess the Efficacy of Sigmart in Patients With Recurrent Angina After Coronary Revascularization [NCT01185015]Phase 40 participants (Actual)Interventional2011-01-31Withdrawn
Effect of Nicorandil, Diltiazem or Isosorbide Mononitrate for Oral Antispastic Therapy After Coronary Artery Bypass Grafting Using Radial Artery Grafts - A Pilot Randomized Controlled Trial [NCT04310995]Phase 4150 participants (Actual)Interventional2020-06-02Completed
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development in Healthy and Insulin Resistant Subjects [NCT03775902]16 participants (Actual)Interventional2018-12-19Completed
Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study): A Investigator-initiated, Control- Randomized, Phase IV Multicenter St [NCT01103336]Phase 4173 participants (Actual)Interventional2010-03-31Completed
Hyperemic Efficacy of Intravenous Infusion of Adenosine in Heart Failure With Reduced Ejection Fraction [NCT03235700]125 participants (Anticipated)Interventional2017-03-01Recruiting
Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction : A Randomized Clinical Trial [NCT02449070]Phase 386 participants (Anticipated)Interventional2015-05-31Recruiting
An Interventional, Pilot Study to Evaluate the Efficacy of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive CAD Patients (SPET Study) [NCT03010423]Phase 48 participants (Actual)Interventional2016-11-30Terminated(stopped due to The study was terminated early, due to the lack of approval of data exportation from the Office of Human Genetic Resource Administration (OHGRA) China.)
Early Administration of Oral Nicorandil in ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial [NCT04632121]300 participants (Anticipated)Observational [Patient Registry]2021-04-01Not yet recruiting
The Preventive Effect of Combined Intracoronary of Nicorandil and Verapamil on Myocardial Injury in Preioperative Period of PCI [NCT05399576]Phase 2150 participants (Anticipated)Interventional2022-05-17Recruiting
Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at the Lebanese American University Medical Center- Rizk Hospital [NCT04631536]Phase 342 participants (Actual)Interventional2021-01-10Active, not recruiting
Effects of Nicorandil on Cardiovascular Events in Patients With Coronary Artery Disease Receiving Hemodialysis [NCT01475123]Phase 4268 participants (Actual)Interventional2008-06-30Active, not recruiting
Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients [NCT02809456]Phase 250 participants (Anticipated)Interventional2016-07-31Enrolling by invitation
A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina. [NCT01397994]Phase 440 participants (Anticipated)Interventional2011-09-30Recruiting
Oral Nicorandil to Reduce Cardiac Death After Coronary Revascularization in Hemodialysis Patients: A Randomized Trial [NCT00848562]129 participants (Actual)Interventional2002-01-31Completed
Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by a K-ATP [NCT00212030]600 participants (Anticipated)Interventional2001-10-31Completed
Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging: SMArT-HS [NCT04120766]Phase 264 participants (Anticipated)Interventional2021-12-01Recruiting
Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [NCT03445728]Phase 4238 participants (Actual)Interventional2018-02-24Completed
Intensive Non-Sympathetic Activating Vasodilatory Treatment in Hypertensive Patients With Microvascular Angina Pectoris [NCT00424801]10 participants (Actual)Interventional2007-01-31Terminated(stopped due to Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis)
Effects of Nicorandil on Cardiac Sympathetic Nerve Activity and Distribution in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention [NCT04826497]Phase 480 participants (Anticipated)Interventional2021-04-30Not yet recruiting
A Randomized, Open Label, Parallel-group Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Di [NCT05427786]Phase 4460 participants (Anticipated)Interventional2022-12-14Recruiting
Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at the Lebanese American University Medical Center- Rizk Hospital [NCT04813471]Phase 370 participants (Anticipated)Interventional2021-01-20Recruiting
Impact of Intravenous Administration of Nicorandil as Adjuncts to Reperfusion Treatment for Acute ST Segment Elevation Myocardial Infarction: a Multi-center Randomized Controlled Trial [NCT04665648]Phase 41,500 participants (Anticipated)Interventional2021-06-01Recruiting
Efficacy of Intracoronary Infusion of Different Medicine With Targeted Perfusion Catheter on Myocardial Perfusion in Patients With STEMI Undergoing Primary PCI:an Open,Prospective,Randomized,Multicenter Trial. [NCT03252665]Phase 4600 participants (Anticipated)Interventional2017-09-01Not yet recruiting
Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction [NCT02435797]Phase 4100 participants (Anticipated)Interventional2015-04-30Recruiting
Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus [NCT02328521]Phase 448 participants (Anticipated)Interventional2014-12-31Recruiting
The Effect of Nicorandil on Left Ventricular Myocardial Strain in Patients With Coronary Chronic Total Occlusion [NCT05087797]Phase 461 participants (Actual)Interventional2019-04-08Completed
A Prospective, Multi-center, Random, Open-label Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina [NCT01396395]Phase 4402 participants (Actual)Interventional2011-09-30Completed
Nicorandil Versus Nitroglycerin for Symptomatic Relief of Angina in Patients With Slow Coronary Flow Phenomenon Visited in Imam Reza Hospital, Mashhad, Iran [NCT02254252]Phase 454 participants (Actual)Interventional2012-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01396395 (16) [back to overview]Change From Baseline in Longest Duration of ST Segment Depression at Week 12
NCT01396395 (16) [back to overview]Change From Baseline in Maximum ST-depression at Week 12
NCT01396395 (16) [back to overview]Change From Baseline in Total Myocardial Ischemic Burden at Week 12
NCT01396395 (16) [back to overview]ECG QT Dispersion
NCT01396395 (16) [back to overview]Frequency of Angina Attack
NCT01396395 (16) [back to overview]Heart Rate Variability (HRV) Rate: Frequency Domain Power-24 Hour
NCT01396395 (16) [back to overview]Number of Myocardial Ischemia Attacks in 24 Hours
NCT01396395 (16) [back to overview]Number of Nitroglycerin Tablets Consumed in a Week
NCT01396395 (16) [back to overview]Number of Subjects Experienced Angina Attack
NCT01396395 (16) [back to overview]Number of Subjects Relieved From Angina Attack After the Consumption of Nitroglycerin
NCT01396395 (16) [back to overview]Number of Subjects Who Showed Compliance to Nicorandil
NCT01396395 (16) [back to overview]Percentage of Subjects Experienced Ischemic Heart Attack During the Six-minute Walk Test
NCT01396395 (16) [back to overview]Walk Distance in Six Minute Walk (6-MWT) Test at Week 12
NCT01396395 (16) [back to overview]Heart Rate Variability (HRV) Rate: Time Domain
NCT01396395 (16) [back to overview]Number of Arrhythmia Occurred Within 24 Hours
NCT01396395 (16) [back to overview]Number of Subjects With Any Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Death, and AEs Leading to Discontinuation
NCT02254252 (3) [back to overview]Angina Episode Frequnecy
NCT02254252 (3) [back to overview]Angina Episode Intensity
NCT02254252 (3) [back to overview]Canadian Cardiovascular Society (CCS) Grading of Angina Pectoris

Change From Baseline in Longest Duration of ST Segment Depression at Week 12

The maximum ST- depression was evaluated from sum of all leads for all the subjects with myocardial ischemia attack. The longest duration of ST segment depression of all leads for all the subjects with myocardial ischemia attack. (NCT01396395)
Timeframe: Baseline, Week 12

Interventionseconds (Mean)
Standard Treatment Plus Nicorandil-3.8
Standard Treatment3.4

[back to top]

Change From Baseline in Maximum ST-depression at Week 12

The maximum ST- depression was evaluated from sum of all leads for all the subjects with myocardial ischemia attack. Absolute value of maximum ST-depression was used for calculation. (NCT01396395)
Timeframe: Baseline, Week 12

Interventionmillimeter (Mean)
Standard Treatment Plus Nicorandil0.25
Standard Treatment0.36

[back to top]

Change From Baseline in Total Myocardial Ischemic Burden at Week 12

The total myocardial ischemic burden was defined as the product of the decrease, total array and total time of ST-segment in symptomatic and asymptomatic myocardial ischemia subjects within 24 hours. (NCT01396395)
Timeframe: Baseline, Week 12

Interventionmillimeter*minutes (Mean)
Standard Treatment Plus Nicorandil-38.63
Standard Treatment29.26

[back to top]

ECG QT Dispersion

The ECG QT dispersion was defined as the difference between the longest (QTmax) and the shortest (QTmin) QT intervals within a 12-lead ECG. (NCT01396395)
Timeframe: At Week 12

Interventionmilliseconds (Mean)
Standard Treatment Plus Nicorandil0.1298
Standard Treatment0.1110

[back to top]

Frequency of Angina Attack

The total number of times angina attacks occurred within a week (number of times/week) (NCT01396395)
Timeframe: At Week 12

Interventionangina attacks per week (Median)
Standard Treatment Plus Nicorandil1
Standard Treatment2

[back to top]

Heart Rate Variability (HRV) Rate: Frequency Domain Power-24 Hour

HRV is the degree of fluctuation in the length of the intervals between heart beats. All HRV parameters are calculated on 'normal-to-normal' (NN) inter-beat intervals (or NN intervals) caused by normal heart contractions. The HRV was evaluated based on frequency domain power-24 hours. (NCT01396395)
Timeframe: At Week 12

Interventionmillisecond square (ms^2) (Mean)
Standard Treatment Plus Nicorandil2397.0
Standard Treatment2328.6

[back to top]

Number of Myocardial Ischemia Attacks in 24 Hours

Myocardial ischemia attack was evaluated by 24-hour Holter monitoring based on the following criteria: 0.08 seconds after the J point in electrocardiogram (ECG) or compared with baseline levels, ST-segment with horizontal or downward sloping down greater than or equal to (>=) 0.1 millivolts (mV), and lasted for >= 1 minute, and at least 1 minute of interval with another ischemic attack, as one array myocardial ischemia. (NCT01396395)
Timeframe: At Week 12

Interventionischemic attacks per 24 hours (Mean)
Standard Treatment Plus Nicorandil2.3
Standard Treatment3.8

[back to top]

Number of Nitroglycerin Tablets Consumed in a Week

(NCT01396395)
Timeframe: At Week 12

Interventiontablets per week (Median)
Standard Treatment Plus Nicorandil1
Standard Treatment2

[back to top]

Number of Subjects Experienced Angina Attack

(NCT01396395)
Timeframe: Baseline up to 12 Weeks

Interventionsubjects (Number)
Standard Treatment Plus Nicorandil48
Standard Treatment70

[back to top]

Number of Subjects Relieved From Angina Attack After the Consumption of Nitroglycerin

(NCT01396395)
Timeframe: At Week 12

Interventionsubjects (Number)
Standard Treatment Plus Nicorandil20
Standard Treatment43

[back to top]

Number of Subjects Who Showed Compliance to Nicorandil

Compliance percent (%) was calculated by using the formula: (actual total dose divided by planned total dose) multiplied by 100. If subject compliance was less than 80% or greater than 120%, then that subject was considered as non compliant. The compliance of subjects taking nicorandil was evaluated. (NCT01396395)
Timeframe: Baseline up to 12 Weeks

Interventionsubjects (Number)
Standard Treatment Plus Nicorandil181

[back to top]

Percentage of Subjects Experienced Ischemic Heart Attack During the Six-minute Walk Test

The percentage of subjects who experienced ischemic heart attack during the Six-minute walk test (6-MWT) were evaluated.The 6-MWT was the distance that a subject could walk in 6 minutes. Subjects were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. The 6-MWT was completed within 1-hour after wearing Holter. (NCT01396395)
Timeframe: At Week 12

Interventionpercentage of subjects (Number)
Standard Treatment Plus Nicorandil2.2
Standard Treatment4.1

[back to top]

Walk Distance in Six Minute Walk (6-MWT) Test at Week 12

The 6-MWT distance was the distance that a subject could walk in 6 minutes. Subjects were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. The 6-MWT was completed within 1-hour after wearing Holter. (NCT01396395)
Timeframe: At Week 12

Interventionmeters (Mean)
Standard Treatment Plus Nicorandil452.1
Standard Treatment438.1

[back to top]

Heart Rate Variability (HRV) Rate: Time Domain

HRV is the degree of fluctuation in the length of the intervals between heart beats. All HRV parameters are calculated on 'normal-to-normal' (NN) inter-beat intervals (or NN intervals) caused by normal heart contractions. Standard deviation of all NN intervals (SDNN) and Standard deviation of the averages of NN intervals (SDANN) are the two time domain methods used to determine heart rate variability. Two variants of the SDNN, created by dividing the 24-hour monitoring period into 5-minute segments, are the SDNN index and the SDANN index. The SDNN index is the mean of all the 5-minute standard deviations of NN (normal RR) intervals during the 24-hour period, while the SDANN index is the standard deviation of all the 5-minute NN interval means. (NCT01396395)
Timeframe: At Week 12

,
Interventionmillisecond (Mean)
SDNN-24 hour (n=141, 149)SDANN index (n=141, 149)SDNN index (n=140, 147)
Standard Treatment125.7116.747.0
Standard Treatment Plus Nicorandil126.1116.947.6

[back to top]

Number of Arrhythmia Occurred Within 24 Hours

The number of ventricular tachycardia and premature ventricular beats that occurred within 24 hours. (NCT01396395)
Timeframe: At Week 12

,
Interventionbeats per 24 hours (Mean)
Ventricular tachycardiaPremature ventricular beat
Standard Treatment5.2569.1
Standard Treatment Plus Nicorandil0.8134.8

[back to top]

Number of Subjects With Any Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Death, and AEs Leading to Discontinuation

An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs were defined as the AEs that occurred between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. (NCT01396395)
Timeframe: From the first dose of study drug administration up to 30 days after the last dose of study drug administration (up to 16 weeks )

,
Interventionsubjects (Number)
TEAEsSAEsAEs Leading to DeathAEs Leading to Discontinuation
Standard Treatment13710
Standard Treatment Plus Nicorandil239116

[back to top]

Angina Episode Frequnecy

One month after treatment, patients were asked to determine the frequency of angina episodes in the preceding week. (NCT02254252)
Timeframe: 1 month

Interventionepisodes per week (Mean)
Nitroglycerin2.28
Nicorandil1.68

[back to top]

Angina Episode Intensity

One month after treatment, patients were asked to determine the average intensity of chest pain in experienced episodes using a Likert-type scale of 0 to 10, where 0 indicated lowest intensity/no pain and 10 indicated the highest possible pain experienced. (NCT02254252)
Timeframe: 1 month

Interventionunits on a scale (Mean)
Nitroglycerin3.89
Nicorandil3.03

[back to top]

Canadian Cardiovascular Society (CCS) Grading of Angina Pectoris

One month after treatment, patients were asked to describe the angina episode and based on their descriptions, the CCS class of chest pain was determined. Based on patient's description of the anginal episodes, angina severity was classified into one of CCS class I (angina only with prolonged demanding physical activity), Class II (Slight limitation, with angina only during vigorous physical activity), Class III (Symptoms with everyday living activities), or class IV (angina at rest). (NCT02254252)
Timeframe: 1 month

,
Interventionparticipants (Number)
CCS Class ICCS Class IICCS Class III
Nicorandil1942
Nitroglycerin8115

[back to top]